

Final Announcement



98th Annual Meeting

British Association of Dermatologists

EDINBURGH

3rd - 5th July 2018



ANTI-SHINE EFFECT



EFFECTIVE SEBUM CONTROL FOR UP TO 8H ANTI-SHINE

Eucerin® Sun Oil Control Dry Touch: superior sun protection for oily, blemish-prone skin – also complementing acne therapy²

- Oil Control Technology: Sebum-regulating formula with lipid-absorbing pigments and L-Carnitine.
- Advanced Spectral Technology: UVA/UVB protection and high-energy visible light defence. Support of skin's own cell repair mechanisms.
- Ultra-light, fast absorbing formula with very good skin tolerability.³

(1) Split-face application of product (right-hand side) and a control sunscreen SPF50+ (left-hand side), clinical photography after 5 min. Example shown, individual results may vary. (2) Product application (n = 1059 patients with blemish-prone skin, 50% received acne medication) twice daily for four weeks. Patient and dermatologist assessment. (3) After a two-week treatment period with daily product application, physician's evaluation in patients with blemish-prone skin (n = 35).



FAST MATTIFYING EFFECT¹

Eucerin® MEDICAL SKIN SCIENCE THAT SHOWS

www.eucerin.co.uk

Beiersdorf

Beiersdorf AG, 20245 Hamburg, Germany

Overview

Monday 2nd July Overview	16	Keynote Lectures	
BSD Self-Assessment	17	Tuesday	
Trainee pre-conference session	18	Dr Eleni Linos	40
SAS Session	19	Dr Wolfgang Weyers	40
		Prof Warren Piette	41
Tuesday 3rd July Overview	20	Wednesday	
British Society of Cutaneous Allergy (BSCA)	21	Prof Hensin Tsao	63
CPCs - Joint BAD / BSD	24		
British Society for Dermatological Surgery (BSDS)	26	Thursday	
British Society for Skin Care In Immunosuppressed Individuals (BSSCI)	31	Prof Hywell Williams	81
British Society for Dermatopathology (BSD)	34		
British Society of Geriatric Dermatology	37	General	
Guest Society Session – British Geriatric Society	38	Hot Topics	86
Dermatology Teachers	39	Pharma Presentations	87
Plenary Session	40	Lunchtime Journal Club	87
		Poster Walks	88
Wednesday 4th July Overview	42		
Sponsored Symposium: Novartis	43		
Plenary session - Medical Dermatology	44		
British Cosmetic Dermatology Group (BCDG)	46		
BADGEM	48		
Sponsored Symposium: Janssen	51		
Sponsored Symposium: UCB Pharma	52		
Sponsored Symposium: Sanofi Genzyme	53		
Submitted papers	54		
British Society for Investigative Dermatology (BSID)	55		
British Teledermatology Society (BTS)	56		
Psychodermatology UK	57		
Historical Symposium	60		
Plenary Session - Melanoma MDT	63		
UK TREND	64		
Sponsored Symposium: Celgene	65		
Sponsored Symposium: LEO Pharma	66		
Thursday 5th July Overview	68		
Sponsored Symposium: Almirall	69		
Sponsored Symposium: Lilly	70		
Professors & Registrars session	71		
BSPD & BSPAR joint session	72		
British Photodermatology Group (BPG)	76		
British Hair & Nail Society (BHNS)	79		
Plenary Session - Tropical Disease	81		
Dermoscopy update teaching session	82		
Advanced Medical Dermatology	83		
Health Service delivery, management research and GIRFT symposium	84		

Organising Committee

Dr Michael Ardern-Jones
Miss Marilyn Benham
Dr Tanya Bleiker - Chair
Mrs Jenna Bowler
Dr Mabs Chowdhury
Mr Chris Garrett
Dr Karen Gibbon

Mrs Catherine Hanaway
Dr Nick Levell
Dr Ruth Murphy
Dr Anshoo Sahota
Dr Amr Salam
Dr Jui Vyas

BAD Abstract Selection Committee

Dr Arti Bakshi
Dr Asok Biswas
Dr Tanya Bleiker
Dr Mabs Chowdhury
Dr Sara Edward
Dr Adam Fityan
Dr Tabi Leslie

Dr Nick Levell
Dr Luisa Motta
Dr Ruth Murphy
Dr Girish Patel
Dr Jane Setterfield
Dr Victoria Swale

BAD Judging Committee

Dr Mike Ardern-Jones
Dr Alison Bedlow
Dr Tanya Bleiker
Prof Sara Brown
Dr Andrew Carmichael
Dr Mabs Chowdhury
Dr Giles Dunnill
Dr Sara Edward
Dr Adam Fityan
Dr Louise Fuller
Dr Mark Goodfield
Dr Jon Goulding
Dr Danielle Greenblatt
Dr Shikha Gupta

Dr Hamish Hunter
Dr Malvina Krupiczojc
Dr Aoife Lally
Dr Tess McPherson
Dr Megan Mowbray
Dr Jana Natkunarajah
Dr Eugene Ong
Dr Shantini Rice
Dr Amr Salam
Dr Victoria Swale - Chair
Dr Donna Thompson
Dr Jui Vyas
Dr Richard Weller

BADGEM Abstract Selection Committee

Prof Sara Brown
Prof Edel O'Toole
Dr Neil Rajan

BCDG Abstract Selection Committee

Dr Anjali Mahto
Dr Bav Shergill
Dr Nisith Sheth

BHNS Abstract Selection Committee

Dr Abby Macbeth
Dr Anita Takwale

BPG Abstract Selection Committee

Dr Giles Dunnill
Dr Hiva Fassihi
Dr Adam Fityan
Dr Victoria Goulden
Dr Sally Ibbotson
Dr Tsui Ling
Dr Paul Norris

Dr Ljubomir Novakovic
Dr Robert Sarkany
Dr Muthu Sivaramakrishnan
Dr Sophie Weatherhead
Dr Chandra Bertram
Dr Johnny Bourke
Dr Cathy Green

BSCA Abstract Selection Committee

Dr Chandra Bertram
Dr Johnny Bourke
Dr Cathy Green

BSPD & BSACI Abstract Selection Committee

Dr Fiona Browne
Dr Liza McCann

Dr Jemima Mellerio
Dr Valerie Rogers

BSD Abstract Selection Committee

Dr Arti Bakshi
Dr Asok Biswas

Dr Sara Edward
Dr Luisa Motta

BSDS Abstract Selection Committee

Dr Vindy Ghura
Dr Wal Hussain

Dr Stephen Keohane
Dr Tom Oliphant

BSSCII Abstract Selection Committee

Dr Tanya Basu
Dr Abha Gulati
Prof Catherine Harwood
Dr Ferina Ismail

Dr Conal Perrett
Prof Charlotte Proby
Dr Mary Wain

BTS Abstract Selection Committee

Dr Carolyn Charman
Dr David de Berker
Dr Saul Halpern

Dermatology Teachers Selection Committee

Dr Anna Ascott
Dr Stuart Cohen
Dr Tamara Griffiths

Dr Maulina Sharma
Dr Minal Singh

Historical Abstract Selection

Dr David Eedy
Dr Julia Ellis
Dr David Gawkrödger
Dr Frances Humphreys
Dr Nick Levell

Prof Rona Mackie
Dr Leslie Millard
Dr Alexa Shipman
Dr Dominic Tabor
Dr Paul Yesudian

Psychodermatology Abstract Selection

Dr Janet Angus
Dr Susannah Baron
Dr Anthony Bewley

A Warm Welcome to Edinburgh 2018

Welcome to Edinburgh and the 98th Annual Meeting of the British Association of Dermatologists. After an extended break of 16 years we are delighted to be back at the Edinburgh International Conference Centre.

Situated at the heart of Scotland's beautiful capital city, the EICC is one of the world's outstanding venues for conferences and events. Edinburgh Airport is just 20 minutes from the city centre and has connections to 120 worldwide destinations. Rail links to the city run all over the UK, with more than 20 daily trains running between Edinburgh and London, taking just over four hours. Edinburgh's compact city centre makes it an ideal city for strolling around. With Edinburgh Castle as your compass, you will find many of the city's attractions within walking distance of the EICC and principal hotels.



Scientific Programme

This year I am delighted to welcome the British Geriatric Society; our joint session will explore the needs of the frail elderly patient. Dr Eleni Linos (San Francisco, USA) will continue this theme in the Tuesday plenary session speaking on 'Skin cancer treatment in the frail elderly: When less is more'.

It is also a great pleasure to introduce our other keynote speakers; Dr Wolfgang Weyers (Freiburg, Germany), Professor Warren Piette (Chicago, USA) and Dr Hensin Tsao (Boston, USA) who will give lectures on, 'Overdiagnosis in skin cancers', 'Reading the skin to recognise the pathophysiology of purpura, vasculitis, and microvascular occlusion' and 'Therapeutic checkmate in melanoma' respectively. I am honoured that Professor Hywel Williams (Nottingham) has agreed to give the Arthur Rook Oration on 'Reducing waste in dermatology research'.

Patients are at the centre of our work; including patient experiences in the 2018 programme has been a priority. We are privileged to have Sarah Burley speak to us on how the new biologics have changed her life with atopic dermatitis and to hear the views of melanoma patients on their experiences during the melanoma multidisciplinary session.

New to this year's annual meeting will be the introduction of poster walks. These take place during every coffee break in the mezzanine poster area. Each walk is themed and will be led by two entertaining and stimulating experts. Places are limited so be sure to sign up early when you arrive in Edinburgh!

On Monday 2nd July, we will be holding pre-conference sessions for trainees, Specialty & Associate Specialist doctors, medical students and there will be a BSD self-assessment session.

Due to the success of last year's BADfest we will again be holding an evening of entertainment, food and drinks on Tuesday. This year there will be a Highland Games theme so practice your Caber tossing and bring your dancing shoes! This event will be taking place in the Strathblane Hall at the EICC. All attendees are invited to attend.

It all promises to be a packed and memorable conference, I look forward to offering a warm welcome to all delegates and hope you enjoy the meeting!

Tanya Bleiker

Dr Tanya Bleiker
Clinical Vice President (2016-2018)

Acknowledgements

The British Association of Dermatologists gratefully acknowledges the contribution of the many exhibitors & sponsors whose attendance has helped make the meeting possible.



Programme Overview

Monday 2nd July 2018

Time	Session Detail	Room	Page
12:45 – 18:15	BSD Self-Assessment	Ochil 1 & 2	17
12:15 – 18:00	Trainee Pre-conference Session	Sidlaw	18
12:15 – 18:00	Staff & Associate Specialist Session	Fintry	19

Tuesday 3rd July 2018

Time	Session Detail	Room	Page
08:00 – 12:00	British Society of Cutaneous Allergy	Fintry	21
08:45 – 10:23	Clinicopathological Cases	Pentland	24
08:45 – 17:00	British Society for Dermatological Surgery	Moorfoot & Kilsyth	26
09:00 – 12:30	British Society for Skin Care in immunosuppressed Individuals	Sidlaw	31
10:30 – 11:00	Hot Topics	Exhibition Hall	86
10:30 – 11:00	Poster Walks	Mezzanine Level	88
11:00 – 15:30	British Society for Dermatopathology	Pentland	34
11:00 – 12:30	British Society of Geriatric Dermatology	Tinto	37
12:15 – 13:00	Pharma Presentations	Lennox Hall	87
12:15 – 12:45	Lunchtime Journal Club	Cromdale Hall	87
13:00 – 14:35	Guest Society Session - British Geriatric Society	Fintry	38
13:15 – 14:15	Dermatology Teachers	Sidlaw	39
14:30 – 15:00	Hot Topics	Exhibition Halls	86
14:30 – 15:00	Poster Walks	Mezzanine Level	88
15:00 – 15:30	Keynote Lecture: Dr Eleni Linos	Pentland	40
15:30 – 16:00	Keynote Lecture: Dr Wolfgang Weyers	Pentland	40
16:00 – 16:30	Keynote Lecture: Prof Warren Piette	Pentland	41
16:30 – 17:00	Invited Lecture: Prof Mike Cork & Sarah Burley	Pentland	41
17:15 – 18:45	AGM – BAD members only	Pentland	
17:00 – 22:00	BADfest	Strathblane Hall	13

Wednesday 4th July 2018

Time	Session Detail	Room	Page
07:30 – 08:30	Christian Medical Fellowship Breakfast	Carrick	
07:45 – 08:30	Novartis Sponsored Symposium	Fintry	43
08:45 – 12:30	Plenary session - Medical Dermatology	Pentland	44

Time	Session Detail	Room	Page
08:45 – 12:30	British Cosmetic Dermatology Group	Moorfoot & Kilsyth	46
09:00 – 12:30	BADGEM	Sidlaw	48
10:30 – 11:00	Hot Topics	Exhibition Halls	86
10:30 – 11:00	Poster Walks	Mezzanine Level	88
13:00 – 14:00	Janssen Sponsored Symposium	Sidlaw	51
13:00 – 14:00	UCB Pharma Sponsored Symposium	Fintry	52
13:00 – 14:00	Sanofi Genzyme Sponsored Symposium	Moorfoot & Kilsyth	53
14:00 – 15:15	Scientific Session – submitted papers	Pentland	54
14:00 – 15:30	British Society for Investigative Dermatology	Carrick	55
14:15 – 16:15	British Teledermatology Society	Fintry	56
14:15 – 17:15	Psychodermatology UK	Sidlaw	57
14:15 – 15:30	Historical Symposium	Tinto	60
15:30 – 16:00	Hot Topics	Exhibition Halls	86
15:30 – 16:00	Poster Walks	Mezzanine Level	88
16:00 – 16:30	Keynote Lecture: Prof Hensin Tsao	Pentland	63
16:30 – 18:00	Plenary Session - Melanoma MDT	Pentland	63
16:30 – 18:00	UK Trend	Tinto	64
18:15 – 19:00	Celgene Sponsored Symposium	Sidlaw	65
18:15 – 19:00	LEO Pharma Sponsored Symposium	Fintry	66

Thursday 5th July 2018

Time	Session Detail	Room	Page
07:45 – 08:30	Almirall Sponsored Symposium	Tinto	69
07:45 – 08:30	Lilly Sponsored Symposium	Kilsyth	70
08:30 – 12:15	Professors & Registrars Session	Pentland	71
08:30 – 12:15	BSPD & BSPAR joint session	Sidlaw	72
08:30 – 12:15	British Photodermatology Group	Fintry	76
10:15 – 10:45	Hot Topics	Exhibition Halls	86
10:15 – 10:45	Poster Walks	Mezzanine Level	88
10:30 – 12:30	British Hair & Nail Society	Moorfoot & Kilsyth	79
12:15 – 12:45	Lunchtime Journal Club	Lennox Hall	87
13:00 – 14:15	Plenary Session - Tropical Disease	Pentland	81
14:15 – 14:30	Presidents Address	Pentland	
14:30 – 15:15	Arthur Rook Oration: Prof Hywel Williams	Pentland	81
15:30 – 17:00	Dermoscopy update teaching session	Sidlaw	82
15:30 – 17:00	Advanced Medical Dermatology: Challenging cases. An interactive session	Fintry	83
15:30 – 17:00	Health service delivery, management research and GIRFT symposium	Tinto	84

The Psoriasis Association has been committed to research for the last 50 years

Psoriasis: Translating Innovation into Personalised Care

Book tickets now for our event at the
Royal College of Physicians, London
on **Friday 2nd November 2018**.

Confirmed speakers include:

Prof Christopher Griffiths, Prof Jonathan Barker,
Prof Catherine Smith, Dr Elise Kleyn

For more information and booking
email conference@bad.org.uk

Bringing together leading researchers
in psoriasis. A joint event with The Dowling Club.

www.psoriasis-association.org.uk

Tel: 01604 251620

Follow us: @PsoriasisUK



The Psoriasis Association

Dick Coles House, 2 Queensbridge,
Northampton NN4 7BF

Registered Charity Number: 257414 Scotland: SC039886



Accommodation

Convention Edinburgh is the official accommodation provider for the 2018 BAD Annual Meeting. To book accommodation for this event, please visit <https://cabsedinburgh.eventsair.com/british-dermatology-annual-meeting-2018/home-page>

App

We will be providing a smartphone conference app for delegates to use during the conference.

The app will provide the following features;

- Review agenda & speakers
- Interactive floorplans
- View abstracts & e-posters
- View sponsors & exhibitors
- CPD certificate (post event)

Badges

Conference badges will be handed to delegates on registration. For security purposes name badges must be worn at all times throughout the meeting. If you lose your badge, a replacement must be obtained at the registration desk.

The RFID badges will enable delegates to touch into sessions for CPD recording.

In addition, some of the exhibiting companies may ask you to tap in at their stand or symposium. Please be aware that by doing this you will be providing your name, postal address and email details and may receive one automatic email from them.

Following delegate feedback from the 2017 Annual Meeting you will also be able to provide the company with an email address of your choice. The email address they receive will be the one that you specifically indicated in the appropriate section on the registration system.

Banking

High street banks can be found within a 5-10 minute walk of the venue in the city centre.

Business Services

The EICC Business Centre is located in the Strathblane Hall and provides a number of services.

Catering

Lunch and all scheduled refreshment breaks will be served from designated points in the Cromdale and Lennox halls.

Certificate of Attendance

Certificates of attendance will be issued after the meeting and sent to your registered email address. They will provide a CPD breakdown of the sessions you have attended.

Please don't forget to tap into sessions.

Cloakroom

The cloakroom is located in the Strathblane Hall, adjacent to the registration area and will be staffed by the EICC daily.

Continuing Professional Development Credits (CPD)

This event is approved for external credit for the CPD scheme of the Federation of Royal Colleges of Physicians of the UK. **Please tap into sessions** to receive a CPD Breakdown on your certificate to be received post meeting. Physicians should record their credits in their diaries, in accordance with the current RCP recommendations.

Exhibition

The exhibition will be located in the Cromdale and Lennox Halls of the EICC and will be open at the following times:

Tuesday 3rd July:	10:00 – 17:00
Wednesday 4th July:	09:00 – 17:00
Thursday 5th July:	09:00 – 14:00

Exhibition Quiz

Exhibition quiz forms will be included in the delegate bags. To participate in the quiz, delegates must visit each participating exhibitor and answer a simple question. Participants must also obtain four answers from the patient support groups, please note you only need four from any of the patient support groups present over the duration of the meeting. All completed quiz forms must be returned to the registration desk by 14:00 on Thursday 5th July. The prizes will be announced after the meeting.

NO Photography

The BAD has received complaints from our speakers about photography taken during presentations. Photography of patients without consent is an offence which is reportable to the GMC. Other photographs may breach copyright. Please do not take photographs during presentations. Presenters are entitled to stop their presentations and ask for offenders to be removed from the session with no reimbursement of fees.

First Aid

First aid support is available onsite; please ask an EICC steward who will be able to assist you.

Parking

There are many car parks in close walking distance to the EICC. National car parks in Edinburgh can be found at www.ncp.co.uk/find-a-car-park. Additionally, there is a car park at the Sheraton Hotel, 150 meters from the

EICC, with limited accessible parking spaces and Semple Street Car Park located 300 meters from the EICC.

Payment of Registration Fees

We would prefer delegates to pay by cheque (pounds sterling drawn on a UK bank only or by sterling bank draft) made payable to the 'British Association of Dermatologists'. Cheques in other currencies cannot be accepted. Alternatively, delegates may pay by credit card and this is encouraged for overseas delegates. Please note that we only accept MasterCard and Visa. American Express cannot be accepted.

Poster Exhibition

The poster exhibition will be located on the mezzanine level (Level -1). The posters will be numbered, and a list is provided at the back of this programme. There will be an e-poster display area showing all the posters submitted. Posters should be removed by 17:00 on Thursday 5th July. Please note that the British Association of Dermatologists cannot be held responsible for any loss or damage to a poster presented during the Annual Meeting.

Poster Walks

Please see further details on page 88.
Please sign up at the poster walk registration desk.

Registration Desk

The registration desk will be located in the Strathblane Hall of the EICC will be staffed by the BAD team during the following hours:

Monday 2nd July	09:00 – 18:00
Tuesday 3rd - Thursday 5th July	08:00 – 18:00

Sponsored Symposia

The following companies will be holding sponsored symposia at the meeting:

Wednesday 4th July

07:45 – 08:30	Fintry	Novartis
13:00 – 14:00	Sidlaw	Janssen
13:00 – 14:00	Fintry	UCB Pharma
13:00 – 14:00	Moorfoot & Kilsyth	Sanofi Genzyme
18:15 – 19:00	Sidlaw	Celgene
18:15 – 19:00	Fintry	LEO Pharma

Thursday 5th July

07:45 – 08:30	Tinto	Almirall
07:45 – 08:30	Kilsyth	Lilly

Speaker Preview

Speaker preview will be located in Soutra Room on the ground level foyer of the EICC, please ask at the registration desk for directions. All presenters must take their memory sticks to speaker preview at least two hours prior to their presentation.

Taxis

Black cabs are often parked outside the EICC. Alternatively, you can ask concierge to call you a taxi.

Venue

The Edinburgh International Conference Centre
The Exchange Edinburgh
150 Morrison St
Edinburgh EH3 8EE

+44 (0) 131 300 3000
www.eicc.co.uk

Well-Being Area

The BAD is pleased to include the well-being area within the Cromdale Hall. Therapists from D-Stress & Go (UK) www.dstress.co.uk are able to provide attendees with a wide variety of therapies which include Shiatsu, Reiki, Seated Acupressure Massage, Indian Head Massage and Thai Yoga Massage.

SANOFI GENZYME



BAD 2018 is grateful to Sanofi Genzyme for sponsoring the well-being area


Wi-Fi

Wi-Fi access is complimentary and widely available

NOVARTIS

BAD 2018 is grateful to Novartis for sponsoring the Wi-Fi

EICC Map
Level 3




Level -1




Level 1



Level -2



Level 0





Social Events

Trainee Evening Event

2 July 2018, Platform 5 Café at the EICC
17:30 - 21:00

The trainee evening event is a great opportunity to meet with colleagues and network in a relaxed and informal setting. Join us for drinks and food at the Platform 5 Café in the EICC.

SAS

2 July 2018, Omar Khayyam
19:30 - 22:00

SAS Doctors are invited to an informal dinner on Monday evening. Omar Khayyam Indian Punjabi Restaurant couples the elegance of the West End with the vibrancy of downtown Edinburgh.

This is a pre-booked event and tickets cost £20.00

BADfest

3 July 2018, EICC
17:00 - 22:00

We hope this will be a perfect opportunity to relax, catch up with old acquaintances and form new friendships. This event will be taking place in the Strathblane Hall of the EICC. All attendees are invited to attend.

BSDS Dinner

3 July 2018, Royal College of Surgeons
20:00 - 23:00

The British Society for Dermatological Surgery will hold a drinks reception followed by a fine dining meal at the Royal College of Surgeons

Ticket cost: £50.00 (reduced cost for trainees: £20.00)
Dress code: Black Tie

BSMD Curry night

4 July 2018, Omar Khayyam
19:00 - 22:30

British Society for Medical Dermatology are hosting a curry night at Omar Khayyam. This Indian Punjabi Restaurant couples the elegance of the West End with the vibrancy of downtown Edinburgh.

This is a pre-booked event and tickets cost £20.00. Places are limited.



PLEASE JOIN US FOR

BADfest

HIGHLAND GAMES

You are invited to join us on

Tuesday 3rd July

5pm – 10pm

Ceilidh Dancing, Highland Games & More

Strathblane Hall, EICC

An evening of networking food
and entertainment

Wednesday 4th July 2018, 13:00–14:00
Sidlaw Auditorium, EICC

JANSSEN SYMPOSIUM AT BAD

Emerging data for guselkumab▼
and other IL-23 inhibitors in psoriasis:
From data to clinical application

Scientific Committee

Professor Chris Griffiths, *Professor of Dermatology, University of Manchester*
Dr Jenny Hughes, *Consultant Dermatologist, Princess of Wales Hospital*

Please join us for this Janssen-sponsored symposium which will focus on the role of IL-23 inhibition in the treatment of psoriasis. Here, you will be provided with an exciting opportunity to review the role of IL-23 in the pathogenesis of psoriasis, along with appraising the clinical data for the IL-23 inhibitors which target this cytokine. These data will then be related to clinical scenarios applicable to your real-world practice. The symposium will conclude with a valuable opportunity to ask questions of the esteemed faculty.



Agenda

- 13:00 Welcome and introduction**
Professor Chris Griffiths
and Dr Jenny Hughes
- 13:10 IL-23 in psoriasis**
Professor Chris Griffiths
- 13:30 Panel discussion and Q&A**
All
- 13:55 Summary and close**
Dr Jenny Hughes



Tremfya ▼ 100 mg solution for injection

PRESCRIBING INFORMATION

ACTIVE INGREDIENT(S): guselkumab.

Please refer to Summary of Product Characteristics (SmPC) before prescribing.
INDICATION(S): Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

DOSAGE & ADMINISTRATION: For use under guidance/supervision of physician experienced in diagnosis and treatment of plaque psoriasis. Subcutaneous injection. Avoid areas showing psoriasis. **Adults:** 100 mg at weeks 0 and 4, followed by maintenance dose every 8 weeks. Consider discontinuation if no response after 16 weeks of treatment. **Children:** No data available in children/adolescents <18 years. **Elderly:** No dose adjustment required, limited information in subjects aged ≥65 years. **Renal & Hepatic impairment:** Not studied.

CONTRAINDICATIONS: Serious hypersensitivity to active substance or excipients; clinically important, active infection.

SPECIAL WARNINGS & PRECAUTIONS: **Infections:** Potential to increase risk. If signs/symptoms of clinically important chronic/acute infection occur, monitor closely and discontinue Tremfya until resolved. **Tuberculosis:** Evaluate patients for TB pre-treatment; monitor for signs/symptoms of active TB during and after treatment. Consider anti-TB therapy prior to Tremfya if past history of latent/active TB and adequate treatment course not confirmed. **Serious hypersensitivity reaction:** If occurs, discontinue Tremfya immediately and initiate appropriate therapy. **Immunisations:** Consider completing all appropriate immunisations prior to Tremfya. Do not use live vaccines concurrently with Tremfya; no data available; before live vaccination, withhold Tremfya for at least 12 weeks and resume at least 2 weeks after vaccination.

SIDE EFFECTS: **Very common:** Upper respiratory infection. **Common:** Gastroenteritis, herpes simplex infections, tinea infections, headache, diarrhoea, urticaria, arthralgia, injection site erythema. **Refer to SmPC for other side effects.**

PREGNANCY: Avoid use of Tremfya; no data. Women of childbearing potential

should use effective contraception during and for at least 12 weeks after treatment.

LACTATION: Discontinue breast-feeding during treatment and up to 12 weeks after the last dose, or discontinue Tremfya.

INTERACTIONS: No dose adjustment when co-administering with CYP450 substrates. Concomitant immunosuppressive therapy or phototherapy not evaluated. **Refer to SmPC for full details of interactions.**

LEGAL CATEGORY: POM.

PRESENTATIONS, PACK SIZES, MARKETING AUTHORISATION NUMBER(S) & BASIC NHS COSTS

PRESENTATIONS	PACK SIZES	MARKETING AUTHORISATION NUMBERS	BASIC NHS COSTS
Pre-filled syringe	X 1	EU/1/17/1234/001	£2250

MARKETING AUTHORISATION HOLDER: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium.

FURTHER INFORMATION IS AVAILABLE FROM: Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG UK.

Prescribing information last revised: November 2017.

Adverse events should be reported.

▼ This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at dsafety@its.jnj.com.

© Janssen-Cilag Limited 2017



Committee Meetings

Monday 2nd July 2018

10:00 – 17:00	BJD Editorial Team Meeting	Carrick
11:00 – 13:00	SAS Sub-committee	Ochil 3
13:00 – 14:00	Education Unit Meeting	Harris 1
16:00 – 18:00	British Association of Dermatologists Officers	Ochil 3
18:30 – 19:30	National Dermatology Trainee Committee	Carrick

Tuesday 3rd July 2018

07:30 – 08:30	British Society for Dermatopathology Executive Committee	Ochil 3
08:00 – 08:30	The British Society of Cutaneous Allergy (BSCA) AGM	Fintry
08:30 – 09:30	BJD Editorial Board Meeting	Harris 2
09:30 – 10:30	Teachers of Undergraduate Dermatology	Harris 1
10:00 – 12:00	Clinical Experimental Dermatology	Harris 2
11:00 – 12:30	Dermatology Industry Group	Carrick
12:00 – 14:00	Community Dermatology	Ochil 3
12:05 – 12:30	British Society for Skin Care in immunosuppressed Individuals AGM	Sidlaw
13:00 – 14:00	Dowling Club Meeting	Ochil 2
13:00 - 14:00	UKKCC Meeting	Harris 1
14:00 – 15:30	Health Informatics Sub-committee	Ochil 1
14:30 – 15:30	British Society for Dermatopathology AGM	Carrick
16:15 – 17:00	British Society for Dermatological Surgery AGM	Sidlaw
17:15 – 18:45	British Association of Dermatologists' AGM (Members Only)	Pentland

Wednesday 4th July 2018

08:00 – 09:00	BADGEM Steering Group Meeting	Harris 2
08:30 – 10:00	UK DCTN Trial Prioritisation Panel	Carrick 3
08:30 – 10:00	British Skin Foundation Grants Advisory	Ochil 3
09:00 – 11:00	British Society for Dermatological Surgery Committee	Ochil 2
10:15 – 11:15	Skin Cancer Prevention Sub-committee meeting	Harris 1
11:00 – 13:00	UK Dermatology Clinical Trials Network AGM	Carrick
11:30 – 12:30	British Association of Dermatologists Officers	Ochil 1
12:00 – 12:30	British Cosmetic Dermatology Group AGM	Moorfoot & Kilsyth
12:30 – 16:00	British Society for Medical Dermatology Committee	Ochil 2
12:30 – 13:30	UK TREND Steering Committee meeting	Ochil 3
13:00 – 14:00	British Association of Dermatologists' Executive Committee	Harris
14:00 – 15:00	BADGEM Informatics sub-group meeting	Ochil 3
16:00 – 18:00	British Society for Investigative Dermatology Committee	Ochil 3
16:00 – 17:00	Therapy & Guidelines Sub-committee	Harris 1
16:00 - 16:15	British Teledermatology Society AGM	Fintry
16:30 – 17:15	Historical Collection Sub-Committee	Ochil 2
17:00 - 18:00	BAD Teledermatology Sub-committee	Harris 2

Thursday 5th July 2018

08:30 – 09:30	Exhibitors' Meeting	Harris
11:30 – 12:30	NIHR NSG	Harris
12:00 – 12:15	British Photodermatology Group AGM	Fintry
12:15 – 13:45	British Society for Paediatric Dermatology Committee	Ochil 2
12:30 – 13:30	British Hair and Nail Society Committee	Ochil 1
15:30 – 17:00	British Photodermatology Group Committee	Ochil 1



Monday Overview

Time	Session Detail	Room	Page
12:45 – 18:15	BSD Self-Assessment	Ochil 1 & 2	17
12:15 – 18:00	Trainee Pre-conference Session	Sidlaw	18
12:15 – 18:00	Staff & Associate Specialist Session	Fintry	19

Notes

6th BSD Dermatopathology Self Assessment

Date: Monday 2nd July
Time: 12:45 - 18:15
Room: Ochil 1 & 2
Chair: Dr Asok Biswas

Programme

12:45 – 13:45	Lunch	Harris 2
13:45 – 15:45		Presentation of Cases 1 - 20
15:45 – 16:15	Break	Harris 2
16:15 – 18:15		Presentation of Cases 21 - 40
18:15		Evaluation forms, certificates and end of session

Royal College of Pathologists approved for CPD maximum of 6 credits

Speakers:

Arti Bakshi	Laszlo Igali
Asok Biswas	Luisa Motta
Rino Cerio	Alistair Robson
Paul Craig	Ed Rytina
Sara Edward	Catherine Stefanato

Notes

Trainee Session

Date: Monday 2nd July
Time: 12:15 - 18:00
Room: Sidlaw
Chair: Dr Amr Salam & Dr David de Berker

Programme

12:15 – 12:55	Lunch	Strathblane Hall
12:55 – 13:00		Welcome and Introduction Dr Amr Salam and Dr David de Berker
13:00 – 13:30	TPC01	A Clinical Approach to Hair Loss Dr David Fenton
13:30 – 14:00	TPC02	Management of Hyperhidrosis Dr Anshoo Sahota
14:00 – 14:30	TPC03	An Overview of the Diagnosis and Management of Photosensitivity Disorders Prof Sally Ibbotson
14:30 – 14:40	TPC04	Trainee Update Dr Amr Salam
14:40 – 14:55	Break	Level 3 Foyer
14:55 – 15:25	TPC05	Using your mobile phone at work Dr Amr Salam & Dr David de Berker
15:25 – 15:55	TPC06	A Practical Guide to Vulval Disease – what you need to know Dr Isabelle Hay
15:55 – 16:25	TPC07	Software is eating the clinic! Prof Jonathan Rees
16:25 – 16:55	TPC08	The Diagnosis and Management of Rosacea Dr Edward Seaton
16:55 – 17:10	Break	
17:10 – 18:00	TPC09	Keynote Lecture: Cutaneous Microvascular Occlusion Prof Warren Piette
18:00 – 21:00		Trainee evening event at Platform 5 Café



Speciality & Associate Specialists Session

Date: Monday 2nd July
Time: 12:15 - 18:00
Room: Fintry
Chair: Dr Jui Vyas & Dr Ausama Atwan

Programme

12:15 – 12:55	Lunch	Strathblane Hall
12:55 – 13:00		Welcome and Introduction Dr Jui Vyas
13:00 – 13:45	SAS01	A practical approach to the diagnosis of Vulval Disorders Dr Natalie Stone
13:45 – 14:30	SAS02	Handy tips for the Dermatological Surgeon Dr Andrew Sherley-Dale
14:30 – 15:15	SAS03	Urticaria: Guidelines and beyond Dr Tabi Leslie
15:15 – 15:30	Break	Level 3 Foyer
15:30 – 16:15	SAS04	Dermoscopic Detection of Amelanotic Melanoma Dr Caroline Mills
16:15 – 17:00	SAS05	Neutrophilic dermatoses Dr Phil Hampton
17:10 – 18:00	SAS08	Keynote Lecture: <i>Please move to the Sidlaw Room</i> Cutaneous Microvascular Occlusion Professor Warren Piette
19:30 – 22:00		SAS evening Dinner at Omar Khayyam



Tuesday Overview

Time	Session Detail	Room	Page
08:00 – 12:00	British Society of Cutaneous Allergy	Fintry	21
08:45 – 10:23	Clinicopathological Cases	Pentland	24
08:45 – 17:00	British Society for Dermatological Surgery	Moorfoot & Kilsyth	26
09:00 – 12:30	British Society for Skin Care in immunosuppressed Individuals	Sidlaw	31
10:30 – 11:00	Hot Topics	Exhibition Hall	86
10:30 – 11:00	Poster Walks	Mezzanine Level	88
11:00 – 15:30	British Society for Dermatopathology	Pentland	34
11:00 – 12:30	British Society of Geriatric Dermatology	Tinto	37
12:15 – 13:00	Pharma Presentations	Lennox Hall	87
12:15 – 12:45	Lunchtime Journal Club	Cromdale Hall	87
13:00 – 14:35	Guest Society Session - British Geriatric Society	Fintry	38
13:15 – 14:15	Dermatology Teachers	Sidlaw	39
14:30 – 15:00	Hot Topics	Exhibition Halls	86
14:30 – 15:00	Poster Walks	Mezzanine Level	88
15:00 – 15:30	Keynote Lecture: Dr Eleni Linos	Pentland	40
15:30 – 16:00	Keynote Lecture: Dr Wolfgang Weyers	Pentland	40
16:00 – 16:30	Keynote Lecture: Prof Warren Piette	Pentland	41
16:30 – 17:00	Invited Lecture: Prof Mike Cork & Sarah Burley	Pentland	41
17:15 – 18:45	AGM – BAD members only	Pentland	
17:00 – 22:00	BADfest	Strathblane Hall	13

British Society for Cutaneous Allergy

Date: Tuesday 3rd July
Time: 08:00 - 12:00
Room: Fintry
Chair: Dr Jason Williams & Dr Johnny Bourke
Dr Deirdre Buckley & Dr Mark Wilkinson

Programme

08:00 – 08:30		AGM
08:30 – 09:00		Prosser White Oration Metal allergy - when and where is it relevant Jacob Thyssen (Copenhagen, Denmark)
09:00 – 09:10	CD01	Assessment of screening questions for metal allergy and fragrance allergy in a patch test population F. Kreeshan and J. Williams
09:10 – 09:20	CD02	Watch and see: drometrizole contact allergic dermatitis J.R. Brockley and D.A. Thomspson
09:20 – 09:30	CD03	'No more cakes and ale': the relevance of a positive patch test to sodium metabisulfite E. McNulty-Brown, W.A. Woo and S. George
09:30 – 09:40	CD04	Contact and photocontact allergy to sunscreens in children: a 12-year review S. Odedra and D.A Thompson
09:40 – 09:50	CD05	<i>N</i> -isopropyl- <i>N</i> -phenyl-4-phenylenediamine as an important occupational and nonoccupational contact allergen: a retrospective analysis of 3380 patients patch tested in Oxford over a 6-year period R. Jarrett, S. Arnold and S. Cooper
09:50 – 10:00	CD06	An unexpected allergen in sunscreen contact dermatitis: VP/eicosene copolymer R. Waas and G. Hil
10:00 – 10:10	CD07	Standard practices and awareness concerning p-phenylenediamine among salons providing eyelash dyeing services L. Ali and S.A. Ghaffar
10:10 – 10:20	CD08	Hairspray hazard: a case series of three patients with facial dermatitis related to contact allergy to acrylates in hairspray S. Shama and P. Todd
10:20 – 10:30	CD09	A remote source of hand dermatitis E. Akufo-Tetteh and D.A. Thompson



10:30 – 11:00	Break	Exhibition Halls
11:00 – 11:20		Guest Lecture Metal allergies and orthopaedic implants: a re-boot Prof David Gawkrödger (Sheffield)
11:20 – 11:30	CD10	The impact of UV exposure on patch testing in clinical practice <u>A. Daunton</u> and J. Williams
11:30 – 11:40	CD11	A case of allergic contact dermatitis to caprylyl glycol, a ‘para-preservative’ in cosmetics and personal care products <u>F. Kreeshan</u> and J. Williams
11:40 – 11:50	CD12	Photocontact dermatitis to ketoprofen: a case report and review of the literature <u>E. Akufo-Tetteh</u> and D.A. Thompson
11:50 – 12:00	CD13	Contact urticaria with anaphylaxis to thiourea, chloroxylenol and chlorocresol <u>S Mehrtens</u> and C. Reckling

Notes



Posters

- | | |
|------|---|
| CD14 | <p>llergic contact dermatitis in atopic individuals: results of a 30-year retrospective study</p> <p><u>Y. Teo</u>, J. MacFadden, I. White, M. Lynch and P. Banerjee</p> |
| CD15 | <p>Ethylhexylglycerin: a case for adding this chemical to the BSCA cosmetic series</p> <p><u>R. Fisher</u> and S. Cooper</p> |
| CD16 | <p>Frontal fibrosing alopecia: possible association with antiaging skincare products</p> <p><u>R. O'Connor</u>, S. McCarthy, M. Murphy and J. Bourke</p> |
| CD17 | <p>A case of unusual pustular allergic contact dermatitis caused by diethylthiourea, featuring a 'flare-up phenomenon' during patch testing</p> <p><u>F. Kreeshan</u> and J. Williams</p> |
| CD18 | <p>A case of methacrylate allergy due to functional electrical stimulation pads with generalization following dental treatment</p> <p><u>R. Jarrett</u> and S. Cooper</p> |
| CD19 | <p>A multicentre audit of occupational dermatoses in the Republic of Ireland</p> <p><u>A. Flynn</u>, A. Money, S. McCarthy, L. Roche, E.N. Dhonncha, O. Molloy, R. O'Connor, S. Menzies, L. Cunningham, M. Sadlier, E. Gilhooley, J. Boggs and J. Bourke</p> |
| CD20 | <p>'Shocking' hot tub dermatitis</p> <p><u>S. Hadjieconomou</u>, T. Hughes and N. Stone</p> |
| CD21 | <p>Cutaneous allergy to black seed oil: the bad side of a good seed</p> <p><u>J.R. Brockley</u> and D.A. Thompson</p> |
| CD22 | <p>Should we routinely test all patients to extended fragrance series?</p> <p><u>R. Fatima</u>, <u>A. Maan</u> and F. Macdonald</p> |
| CD23 | <p>Benzoic acid in oral disease: a case series of delayed contact sensitization</p> <p><u>R. Kumari</u> and D.A. Thompson</p> |
| CD24 | <p>Benzoic acid: an unusual cause of dermatitis medicamentosa</p> <p><u>R. Kumari</u> and D.A. Thompson</p> |
| CD25 | <p>Topical chloramphenicol for minor surgical wounds: – first do no harm?</p> <p><u>M.R. Panchal</u> and G. Johnston</p> |
| CD26 | <p>Contact urticaria: a case series</p> <p><u>R. Kumari</u> and D.A. Thompson</p> |

The poster viewing session will take place during the lunch break on Tuesday 3rd July



Joint meeting with the British Society of Dermatopathology

Date: Tuesday 3rd July
Time: 08:45 – 10:23
Room: Pentland
Chair: Dr Sara Edward & Dr Victoria Swale

Programme

- | | | |
|---------------|-------|---|
| 08:45 – 08:52 | CPC01 | <i>Mycobacterium chelonae</i> skin infection following tattooing: a report of four cases in South Wales
<u>A. Atwan</u>, P. Srivastava, M.M.U. Chowdhury and N.M. Stone |
| 08:52 – 08:59 | CPC02 | Impact of AJCC 8th Edition on the staging of cutaneous squamous cell carcinoma
<u>G. Heuston</u> and C. Heffron |
| 08:59 – 09:06 | CPC03 | A rare variant of the blue naevus
<u>W.A. Woo</u>, J. Coe, G. Springgay and P. Gupta |
| 09:06 – 09:13 | CPC04 | Nivolumab-induced sarcoidosis in a patient with advanced urothelial carcinoma mimicking tumour progression
<u>A. Randhawa</u>, M. Paul and I. Ngu |
| 09:13 – 09:20 | CPC05 | Systemic follicular B-cell lymphoma presenting as an inflammatory scalp dermatosis
<u>I. Kreuser-Genis</u>, J. Goodlad, R. Jackson, P. MacKay, I. Ngu and R. Gardner |
| 09:20 – 09:27 | CPC06 | On the fringe of melanoma: an unsuspected forehead collision
<u>A. Wernham</u>, R. Hejmadi, O. Cain and S. Velangi |
| 09:27 – 09:34 | CPC07 | Pembrolizumab-induced morphea in a patient treated for metastatic melanoma
<u>C. Broderick</u>, R. Atkar, E. Rytina and M. Wallace |
| 09:34 – 09:41 | CPC08 | The toxic host: GVHD vs. TEN
<u>A. Randhawa</u>, L. Melly, A. Drummond and G. Wylie |
| 09:41 – 09:48 | CPC09 | Dermatomyositis with a vesiculobullous eruption: a rare entity
<u>B. Ganatra</u>, D. James and J. Natkunarajah |
| 09:48 – 09:55 | CPC10 | Squamous cell carcinomas in Blaschkoid epidermal naevi
<u>A. Dubois</u>, S. Rannan-Eliya, N. Rajan and T. Oliphant |
| 09:55 – 10:02 | CPC11 | Sarcoidosis mimicking scleroderma
<u>T. Ahad</u> and T. Clayton |

- | | | |
|---------------|-------|--|
| 10:02 – 10:09 | CPC12 | Multiple facial ulcers: do you smell a rat?
<u>L.Y. Kuan</u> and J.Y. Pan |
| 10:09 – 10:16 | CPC13 | Melanoma arising within large 'speckled' melanocytic naevi
<u>S. Muthiah</u>, M. Arefi, A. Carmichael, P. Brennan, P. Barrett, J. Langtry, J. Burn, A. Husain, T. Oliphant and N. Rajan |
| 10:16 – 10:23 | CPC14 | Multiple BAP1 inactivated Naevi: sentinel markers of suspected germline <i>BAP1</i> mutated cancer family
<u>L. Nestor</u>, J. Aird, R. Coleman, P. Ormond, N. Leonard, C. Healy, E. Calonje, D. Gallagher, F. Kelleher and M. McMenamin |

Notes

British Society for Dermatological Surgery

Date: Tuesday 3rd July
Time: 08:45 - 17:00
Room: Moorfoot & Kilsyth
Chair: Dr Vindy Ghura & Dr Walayat Hussain
Dr Thomas Oliphant & Dr Steve Keohane
Dr Vindy Ghura & Dr Steve Keohane

Programme

08:45 – 08:52	DS01	Cochrane systematic review of the diagnostic accuracy of reflectance confocal microscopy for detection of melanoma J. Dinnes, J. Deeks, D. Saleh, N. Chuchu, S. Bayliss, L. Patel, C. Davenport, Y. Takwoingi, K. Godfrey, R. Matin, R. Patalay and H. Williams
08:52 – 08:59	DS02	Cochrane systematic review of diagnostic accuracy of dermoscopy in comparison to visual inspection for the diagnosis of melanoma R.N. Matin, N. Chuchu, J. Dinnes, J.J. Deeks, L. Ferrante di Ruffano, D.R. Thomson, K.Y. Wong, R.B. Aldridge, R. Abbott, M. Fawzy, S.E. Bayliss, M.J. Grainge, Y. Takwoingi, C. Davenport, K. Godfrey, F.M. Walter and H. Williams
08:59 – 09:06	DS03	Ten years experience of the Johnson Square procedure for lentigo maligna and lentigo maligna melanoma H. Smith, B. Olabi, A. Patel, S. Varma and M. Lam
09:06 – 09:13	DS04	Acral lentiginous melanoma: is inflammation the missing link? H. Peach and F. Al-Hassani
09:13 – 09:20	DS05	No relationship found between serum vitamin D levels and prognostic indices of malignant melanoma, in contrast to previous studies B. Olabi, H. Smith, A. Panthagani, S. Ratib, M. Lam and S. Varma
09:20 – 09:27	DS06	Mohs in the twilight zone N. Spierings, S. Turvill and W. Hussain
09:27 – 09:34	DS07	Survey of forehead flap use among U.K. dermatological surgeons S. Manam, D. Brass, C. Lawrence, T. Oliphant and J. Langtry
09:34 – 09:41	DS08	Do perioperative antibiotics reduce the risk of surgical site infections following excision of ulcerated skin cancers? A critically appraised topic S.A. Chan, A. Wernham, N. Stembridge, N. Harper, S. Verykiou, G. Fremlin, R. Abbott and R. Matin
09:41 – 09:48	DS09	Antiseptic use in Mohs surgery: British Society for Dermatological Surgery and Australasian College of Dermatologists Mohs Member Survey B. Swan, R. Patalay and R. Mallipeddi

09:48 – 09:55	DS10	Abstract withdrawn
09:55 – 10:02	DS11	Adequate histological margins for basal cell carcinoma K.N. Roszpopa and G. Colver
10:02 – 10:09	DS12	QUICK FIRE RECON Flipped Island pedicle flaps in dermatological surgery H. Cordey, C. Fleming and A. Affleck
10:09 – 10:16	DS13	Deroofing surgery for advanced hidradenitis suppurativa (Hurley III): a preferred patient choice to wide excision and reconstruction M. Schenker
10:16 – 11:00	Break	Exhibition Halls
11:00 – 11:07	DS14	'Doughnut' Mohs micrographic surgery in the treatment of extramammary Paget's disease at a specialist skin cancer referral centre C. Peng, A. Martin-Clavijo and S. Velangi
11:07 – 11:14	DS15	Curretage debulk prior to Mohs micrographic surgery does not affect the number of Mohs stages P. Jayasekera, D. Brass, T. Oliphant, J. Langtry, J. Dodd and C. Lawrence
11:14 – 11:21	DS16	Use of reflectance confocal microscopy in a U.K. secondary care environment shows a high correlation between histological and confocal diagnosis of both melanoma and basal cell carcinoma (BCC) H. Stevens, J. El Jabbour and R. Stevens
11:21 – 11:28	DS17	Dermoscopic features of amelanotic/hypomelanotic melanoma: a review of 17 cases A. Atwan and C. Mills
11:28 – 11:35	DS18	Recurrent basal cell carcinoma at high-risk facial sites following treatment with electrochemotherapy S. Manam, T. Oliphant, J. Langtry and C. Lawrence
11:35 – 11:42	DS19	QUICK FIRE RECON Call on the horn when in difficulty in the alar region! T. Ahad and V. Ghura
11:42 – 11:49	DS20	Spotlight on lentigo maligna Z.C. Venables, E. Craythorne, I.M. Leigh and R. Patalay
11:49 – 11:56	DS21	High-risk SCC: Sorting the wolves from the sheep C. Kiely, R. Mallipeddi and E. Craythorne
11:56 – 12:03	DS22	Local anaesthesia and tourniquet practices in digital surgery: a survey of BSDS members S. Fenwick, S. Muthiah, S. Verykiou, T. Oliphant, C. Lawrence, D. Brass, K. Blasdale and J. Langtry
12:03 – 12:10	DS23	Growth rates of basal cell carcinoma prior to Mohs micrographic surgery: should some patients be prioritized on the waiting list? D. Tabor, S. Ball, D. Veitch, L. Naysmith and S. Rice



12:10 – 12:17	DS24	Lines under the eyes: 17 new cases of linear basal cell carcinoma <u>N. Collier, N. Telfer and V. Ghura</u>
12:17 – 12:24	DS25	Implantable cardiac devices: awareness of and compliance with new guidelines during dermatological surgical procedures <u>S. Muthiah, S. Verykiou, S. Fenwick, T. Oliphant, D. Brass, C. Lawrence, J. Langtry and K. Blasdale</u>
12:24 – 12:31	DS26	Excision of the entire nail apparatus: indications and outcomes in 23 patients <u>S. Verykiou, T. Oliphant, D. Brass, C. Lawrence and J. Langtry</u>
12:31 – 13:30	Lunch	Exhibition Halls
13:30 – 14:15		Focus Session Laser and Surgical top tips Dr Vishal Madan (Manchester)
14:15 – 14:45		Guest Lecture Developing clinical trials in dermatological surgery Prof Hywel Williams (Nottingham) The lack of good evidence in the form of randomised controlled clinical trials for most surgical interventions has been a topic of derision for many years. But with the advent of the IDEAL collaboration (Idea, Development, Exploration, Assessment, Long-term Follow-up, Improving the Quality of Research in Surgery) and several outstanding leaders in evidence-based surgery, things have changed considerably over the last 10 years. In this talk, I shall provide a basic description of the main threats to validity in surgical trials, and concentrate on those biases that may be particularly troublesome such as equipoise issues, learning curves, waiting list bias, and the importance of understanding surgery as a complex intervention involving pre-op and post-op care as well as the actual surgical technique. My aim is to encourage you to get involved in developing and delivering surgical trials in dermatology through the BSDS and UK Dermatology Clinical Trials Network. Together, we could be world leaders in this field.
14:45 – 15:00	Break	Exhibition Halls
15:00 – 15:30		Guest Lecture: Dr Eleni Linos (San Francisco, USA) - Pentland
16:15 – 17:00	AGM	Sidlaw



Posters

DS27	Novel benefits of intraoperative intranasal packing (MeroceI) to the dermatological surgeon <u>M. Lam and S. Varma</u>
DS28	A potential role for reflectance laser confocal microscopy in skin cancer clinic: a NICE-directed epidemiological data study <u>K. Sinha, N. Attard, E. Craythorne and R. Patalay</u>
DS29	Cutaneous and superficial soft tissue sarcoma: a tertiary referral centre 5-year experience <u>I. Logan, E. Ong, C. Angwin, F. Le Grange and C. Perrett</u>
DS30	Improving dermatological surgery services using a surgical safety audit <u>D. Veitch, J. Coleman, U. Nguyen, B. Afzal, J. McKenna and R. Burd</u>
DS31	A ‘Never’ event in skin surgery – using the wrong pack: survey of BSDS members’ use of Mohs packs <u>M. Lam and S. Varma</u>
DS32	Noncardiac implantable devices and electrosurgery in procedural dermatology <u>S. Verykiou, S. Muthiah, S. Fenwick, T. Oliphant, D. Brass, C. Lawrence, J. Langtry and K. Blasdale</u>
DS33	Patients underestimate scar size after Mohs micrographic surgery <u>W. Fix, C. Miller, T. Shin, N. Howe, M. Bhatt and J. Sobanko</u>
DS34	Preliminary experience of reflectance confocal microscopy in diagnosing basal cell carcinoma in an NHS setting <u>M. Fadhil, E. Tan, M. Moncrieff, G. Pellacani and J. Garioch</u>
DS35	Healing by secondary intention on the nose: an evaluation of patient satisfaction after Mohs micrographic surgery for basal cell carcinomas <u>M.-A. Gkini, H. Leeman and A. Sahota</u>
DS36	Survey: skin preparation choices amongst BSDS membership and experience of adverse effects <u>M.E. Farrugia, L. Naysmith and S.A. Rice</u>
DS37	Mohs surgery for chondroid syringoma <u>S. Verykiou, T. Oliphant, D. Brass, N. Rajan and J. Langtry</u>
DS38	Keratoacanthoma management: results of a survey of U.K. dermatologists and surgeons <u>R.E. Watchorn, S. Thomas, C. Miller, R.A. Carr, D. Koch, P. Thomas and S.M. Taibjee</u>
DS39	Integrating dermatology and plastic surgery in managing patients with complex facial BCCs in a tertiary referral clinic <u>B. Guha-Niyogi, P. Athavale and M. Wiener</u>
DS40	Laser hair epilation: is there a role in pilonidal sinus disease? <u>S. Odedra, A. Abdullah, M. Thomson and K. Kitching</u>
DS41	Transplantation of combination of noncultured epidermal cell suspension and noncultured dermal cell suspension versus noncultured epidermal cell suspension alone in Vitiligo: a prospective pilot study <u>V. Thakur, D. Parsad, S. Kumaran, S. Kumar and N. Srivastava</u>
DS42	A granular cell tumour of the foot – successful management with Mohs micrographic surgery <u>P. Babakinejad, S. Natarajan, H. Akhtar and T. Oliphant</u>

- DS43

When something gets up your nose a joint approach is often best: report of intranasal basal cell carcinoma with review of the literature
L. Griffin, B. Ranganathan, T. Woolford and V. Ghura
- DS44

A comparison of dermatologist versus non dermatologist excisions of basal cell carcinomas
A. Rogers and G. Belgi
- DS45

The use of Entonox as a dissociative anaesthesia during the injection of botulinum toxin for the treatment of palmar/plantar hyperhidrosis and the DLQI outcomes for these patients
A. Ryan, S. Hill and A. Sahota
- DS46

The use of the therma probe biosensor in aiding the assessment and management of skin lesions
M. Patel, N. Alwash and C. Degiovanni
- DS47

A unique case of inoperable basal cell carcinoma due to the presence of a cochlear implant
A. Sharma and S. Varma
- DS48

Should we re-evaluate the need for preoperative surgical site hair removal?
A. Maan and G. Wylie
- DS49

Patient perspective on individualized letters pre-Mohs surgery
H. Cordey and A. Affleck
- DS50

Issues encountered in dermatologic surgery in patients with Ehlers–Danlos syndrome: a case report and recommendations for practice
M.E. Farrugia, L. Naysmith, J. Langtry, C. Lawrence and S.A. Rice
- DS51

First report of dermatofibrosarcoma protuberans in siblings treated with Mohs micrographic surgery
H. Smith, M. Lam and A. Patel
- DS52

When is a BCC not a BCC?
C. Cotter, A.M. Tobin, R. O'Connor, C. Gallagher and M. Connolly
- DS53

Mohs surgery for buccal mucosa basal cell carcinoma
H. O'Neill, M. Lam, J. Pollock and S. Varma
- DS54

Can we reach a consensus margin policy for Lentigo Maligna?
J. Slater, S. Cliff, F. Pakzad, M. Ajaz and S. Sewell
- DS55

Infection rates post-Mohs micrographic surgery in a tertiary referral centre
A. Victor, A. Martin-Clavijo, S. Rajpar and P. Gazzani

The poster viewing session will take place during the lunch break on Tuesday 3rd July

British Society for Skin Care in Immunosuppressed Individuals

Date:

Tuesday 3rd July

Time:

09:00 – 12:30

Room:

Sidlaw

Chair:

Dr Tanya Basu & Dr Conal Perrett
Prof Catherine Harwood & Dr Helen Ramsay

Programme

09:00 – 09:05		Welcome & Introduction Prof Charlotte Proby (Dundee)
		CLINICAL CASES AND RESEARCH REPORTS
09:05 – 09:10	BI01	Disseminated histoplasmosis as a presenting feature in HIV infection <u>J. Callander</u>, K. Krishnakumar, V. Kumarasamy, S. Murugusundaram, P. Yesudian and P.D. Yesudian
09:10 – 09:17	BI02	A comparison of organ transplant recipients who develop cutaneous basal cell versus squamous cell carcinoma <u>S. Menzies</u>, G. O'Callaghan, E. O'Leary, S. Deady, C. MacEochagain, B. Gadallah, P. Lenane, D. Houlihan, P. Morris, D. Sexton, A. McCormick, J. Egan, J.P. O'Neill, A. Lally, P. Conlon and F. Moloney
09:17– 09:22	BI03	Cutaneous and pulmonary phaeohyphomycosis secondary to <i>Alternaria</i> species in a cardiac transplant recipient <u>A. Spencer</u>, D. Chandler, M. Khan, M. Fitzgerald, J. Weir and F. Teixeira
09:22 – 09:29	BI04	The burden of cutaneous disease in solid organ transplant recipients with skin of colour <u>J. Kentley</u>, L. Mitchell, C. Harwood, J. McGregor and C. Proby
09:29 – 09:34		DISCUSSION TIME
09:34 – 09:41	BI05	Clinicians' attitudes to photoprotection in inflammatory bowel disease patients on immunosuppression <u>C. Gallagher</u>, A. Ridge, D. Kevans, D. McNamara and A.-M. Tobin
09:41– 09:48	BI06	A retrospective clinicopathological review of individuals with coexisting melanoma and chronic lymphocytic leukaemia R.M. Fisher, C.M. Proby, A. Lally, N. Reza, F. Tasker, G. Gupta, <u>C. Glen</u>, F. Ismail, D. Koumaki, J. Lear, A. Khoo, Z.-u. Hasan, C. Foley, R. Abbott, T.N. Basu, C.A. Harwood and R.N. Matin

09:48 – 09:53	BI07	Metastatic squamous eccrine ductal carcinoma in an organ transplant recipient: a diagnostic and management challenge S. Hogan, N. Wijesuriya, D. Markiewicz, R. Cerio, G. Moir, O. Gilleard and C. Harwood
09:53 – 10.00	BI08	The development of a novel educational tool targeted at IBD patients on immunosuppression C. Gallagher, C. Tersaruolo, A. Ridge, D. Kevans, D. McNamara and A.-M. Tobin
10:00 – 10.05		DISCUSSION TIME
10.05 – 10:40	BIGL	Guest Lecture - Introduced by Dr Tanya Basu The changing face of HIV in Dermatology Dr David Paige (London)
10:40 – 11:10	Break	Exhibition Halls
CLINICAL CASES AND RESEARCH REPORTS		
11:10 – 11:15	BI09	Leprosy in immune reconstitution inflammatory syndrome Y. Teo, S. Walker, D. Lockwood, A. Giles, S. Hoque and P. Banerjee
11:15 – 11:20	BI10	A challenging case of persistent pseudomonas in an immunocompromised patient L. Mathew, E. McNulty-Brown and C. Degiovanni
11:20 – 11:25	BI11	The perfect storm – a case of atypical presentation, immunosuppression and antibiotic resistance E. Twigg, P. Hunasehally, M. Brown, N. Karunaharan, A. Malone and L. Munthali
11.25 – 11.30	BI12	Majocchi granulomata in the transplanted host D. Maslin, D. Enoch, E. Rytina and T. Ha
11.30 – 11.35		DISCUSSION TIME
11:35 – 11:40	BI13	Fingolimod-induced primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma A. Connolly, V. Grandi, C. Stephanato, R. Palmer and S. Whittaker
11:40– 11:45	BI14	A solitary cutaneous CMV ulcer revealing advanced HIV immunosuppression A. Kanji, H. Ibrahim and V. Swale
11:45– 11:52	BI15	Dermatological diagnoses and HIV treatment status: A single centre HIV walk-in clinic experience S. Morrow, I. Logan and L. Waters
11:52 – 12:00	BI16	The role of the dermatologist in the haematology ward: our experience in a major haematopoietic stem cell transplant centre Z. Willsmore, G. Mufti, T. Pagliuca and T. Basu
12.00 – 12.05		DISCUSSION TIME
12:05 – 12:30		AGM All BSSCII members most welcome and invited to contribute

Posters

BI17	Trichodysplasia spinulosum in adult organ transplant recipients F. Poon and R.N. Matin
BI18	Abstract withdrawn
BI19	Eruptive acral melanocytic naevi following treatment of metastatic germ cell tumour D. Chandler and C. Borysiewicz
BI20	Medication-related osteonecrosis of the jaw: should dermatology patients being started on systemic corticosteroids be advised to have a routine dental examination first? R. Jones, E. Besi and M. Tidman
BI21	Doctor, my skin feels like a hedgehog? K. Naidoo, L. Thomas, R. Ellis and S. Fatah
BI22	Pyoderma gangrenosum ulcers treated with novel micropore particle technology M.-L. Lovgren, A. Wernham, M. James and A. Martin-Clavijo
BI23	Not all granulomas are cutaneous sarcoidosis U. Popli and P.D. Yesudian
BI24	Hydroxycarbamide-induced facial ulcers M.A. Balogun, O. Johnson and J.M.R. Goulding
BI25	Ustekinumab treatment of ulcerative colitis-associated pyoderma gangrenosum in a patient with adalimumab-induced renal failure G. Haebich, K. May and G.K. Patel
BI26	Duodenal villous atrophy from mycophenolate in pemphigus vulgaris Y. Teo, R. Groves and E. Benton
BI27	A rare case of iatrogenic Kaposi sarcoma secondary to low dose corticosteroid therapy T.S. Chohan, S. Odedra, R.S. Chohan and C. Diaz
BI28	Widespread warts in an immunosuppressed host disguised as a papulosquamous eruption J. Denny, N. Valiallah and J. Natkunarajah
BI29	Treatment of psoriasis with secukinumab (realworld data) at a tertiary hospital in Wales K.S. Mukkanna and M. Kalavala
BI30	A case of cutaneous chronic lymphocytic leukaemia (CLL) of the vulva A. McMullan, A. Evans and C. Green
BI31	Unilateral loss of vision in a patient on biological therapy for multisystem sarcoidosis M.-C. Wilmot and N. Morar

The poster viewing session will take place during the lunch break on Tuesday 3rd July



Posters

- | | |
|------|---|
| DP12 | Plaques and nodules on the posterior lower legs
<u>E. O'Brennan, N. Meara, A. Bakshi and E. Domanne</u> |
| DP13 | A U.K. case of indeterminate dendritic cell tumour
<u>O. Jagun, W. Machado and P. Hiley</u> |
| DP14 | Clinicians aware: pseudoepitheliomatous hyperplasia with Candida masquerading an underlying squamous cell carcinoma
<u>J. Denny, N. Valiallah and J. Natkunarajah</u> |
| DP15 | Diverse proliferative indices of benign cutaneous cylindroma and spiradenoma: limitations of Ki-67 as a discriminator of malignancy
<u>N. Stefanos and N. Rajan</u> |
| DP16 | Sézary Syndrome: the first case described with renal involvement
<u>D. Veitch, K. Wickenden, M. Graham-Brown, J. Dormer, G. Warwick, S. Wagner, R. Burd and J. Burton</u> |
| DP17 | Radiotherapy-induced Toxic epidermal necrolysis
<u>C.Y. Kuah, J.J.L. Gan, I. Ansari, G. Sioftanos and K. Madhavan</u> |
| DP18 | Penile intraepithelial neoplasia presenting as a fissure
<u>N.F. Mahmood and T.N. Shim</u> |
| DP19 | Sclerosing lipogranuloma and necrosis of the penis secondary to kanamycin self-injection
<u>C. Hayes, A. Levene and B. De Silva</u> |
| DP20 | Squamous cell carcinoma and multiple familial trichoepitheliomas: a recurrent association
<u>A. Dubois, T. Mestre, T. Oliphant, A. Husain and N. Rajan</u> |
| DP21 | Diffuse large B-cell lymphoma with atypical clinical presentation as striking annular and arcuate skin lesions with indolent clinical course, absence of systemic involvement and histologically mimicking interstitial granulomatous dermatitis
<u>S. Babu, M. Grainger, I. Pearson, R. Walewska, S. Austin, W. Kempf, A. Robson, R. Carr and S. Taibjee</u> |
| DP22 | Lepromatous leprosy and erythema nodosum leprosum
<u>A. Ascott, S. Nasir, D. Lockwood, S. Abraham, D. Markiewicz and C. Harwood</u> |
| DP23 | Langerhans cell histiocytosis associated with Erdheim–Chester disease
<u>D. Chandler and C. Borysiewicz</u> |
| DP24 | Kaposi sarcoma: is it still an AIDS defining illness? Disseminated cutaneous Kaposi sarcoma in an HIV patient with an undetectable viral load, normal CD4 count and bland histology
<u>L. Webber, Y. Zhang and J. Angus</u> |

The poster viewing session will take place during the lunch break on Tuesday 3rd July

British Society of Geriatric Dermatology

Date: **Tuesday 3rd July**

Time: 11:00-12:30

Room: Tinto

Chair: Dr Sarita Singh

Programme

11:00 – 11:45	SG1	How to prevent penis cancer Prof Chris Bunker (London)
----------------------	-----	--

11:45 – 12:30 AGM

Notes

Date: Tuesday 3rd July
Time: 15:00-17:00
Room: Pentalnd
Chair: Dr Nick Levell & Dr Tanya Bleiker

15:00 – 15:30 **Keynote Lecture - Introduced by Dr Tanya Bleiker**

Skin cancer treatment in the frail elderly: When less is more
Dr Eleni Linos (San Francisco, USA)

Eleni Linos will discuss data on over-diagnosis and over-treatment of skin cancer at the end of life, barriers to personalised treatment, the role of shared decision-making and future directions.



15:30 – 16:00 **Keynote Lecture – Introduced by Dr Nick Levell**

Overdiagnosis in skin cancers

Dr Wolfgang Weyers (Freiburg, Germany)

Efforts at early detection of cancer have resulted in a sharp increase of overdiagnoses, i.e., benign lesions being misinterpreted as malignant ones. Clinical overdiagnoses usually prompt a biopsy to be performed. The number of biopsies has risen dramatically, and the average time and diligence devoted to them have decreased. Biopsy specimens are often extremely small and sometimes crushed, leading to great difficulties in the assessment of histopathologic findings. In their fear not to overlook a malignant lesion, histopathologists confronted with an equivocal lesion tend to err on the malignant side, the results being histopathologic overdiagnoses and overtreatment. Epidemiologists have tried to counter those problems by cautioning against cancer screening and by inaugurating a change in nomenclature: the term “cancer” has been reserved for lesions likely to result in death, whereas earlier stages of the same process are referred to by different names emphasizing their ostensible innocuousness, and any diagnosis of a malignant neoplasm that does not produce symptoms or kill the patient is qualified as “overdiagnosis.” In contrast to those suggestions that ignore biologic entities and sacrifice the foundations of morphologic diagnosis, measures are discussed that may help to overcome the problem of overdiagnosis and overtreatment in more substantial fashion.



16:00 – 16:30 **Keynote Lecture – Introduced by Dr Nick Levell**

Reading the Skin to Recognise the Pathophysiology of Purpura, Vasculitis, and Microvascular Occlusion

Prof Warren Piette (Chicago, USA)

This talk will focus on the use of purpura lesional morphology and number/distribution patterns to focus diagnostic and therapeutic efforts in patients with purpura. The differential diagnosis of purpura includes hundreds of possibilities. It is useful to have a technique to focus diagnostic considerations. Moreover, illness in severely ill patients may evolve more rapidly than laboratory tests can confirm. Also, it is possible for patients to have more than one pathway contributing to their purpuric syndrome. Bedside clues can be crucial in unravelling the diagnostic puzzle.



16:30 – 17:00 **Invited Lecture**
 Sarah Burley: My life with Severe Atopic Eczema
Sarah Burley (Birmingham) & Prof Mike Cork (Sheffield)

Notes

Time	Session Detail	Room	Page
07:30 – 08:30	Christian Medical Fellowship Breakfast	Carrick	
07:45 – 08:30	Novartis Sponsored Symposium	Fintry	43
08:45 – 12:30	Plenary session - Medical Dermatology	Pentland	44
08:45 – 12:30	British Cosmetic Dermatology Group	Moorfoot & Kilsyth	46
09:00 – 12:30	BADGEM	Sidlaw	48
10:30 – 11:00	Hot Topics	Exhibition Halls	86
10:30 – 11:00	Poster Walks	Mezzanine Level	88
13:00 – 14:00	Janssen Sponsored Symposium	Sidlaw	51
13:00 – 14:00	UCB Pharma Sponsored Symposium	Fintry	52
13:00 – 14:00	Sanofi Genzyme Sponsored Symposium	Moorfoot & Kilsyth	53
14:00 – 15:15	Scientific Session – submitted papers	Pentland	54
14:00 – 15:30	British Society for Investigative Dermatology	Carrick	55
14:15 – 16:15	British Teledermatology Society	Fintry	56
14:15 – 17:15	Psychodermatology UK	Sidlaw	57
14:15 – 15:30	Historical Symposium	Tinto	60
15:30 – 16:00	Hot Topics	Exhibition Halls	86
15:30 – 16:00	Poster Walks	Mezzanine Level	88
16:00 – 16:30	Keynote Lecture: Prof Hensin Tsao	Pentland	63
16:30 – 18:00	Plenary Session - Melanoma MDT	Pentland	63
16:30 – 18:00	UK Trend	Tinto	64
18:15 – 19:00	Celgene Sponsored Symposium	Sidlaw	65
18:15 – 19:00	LEO Pharma Sponsored Symposium	Fintry	66



Sponsored Symposium: Novartis

Date: Wednesday 4th July
Time: 07:45 – 08:30
Room: Fintry
Chair: Dr Clive Grattan & Dr John Reed



Programme

Redefining the paradigm for chronic spontaneous urticaria patients

- | | |
|----------------------|---|
| 07:45 – 07:50 | Welcome & Introduction
Dr Clive Grattan (London) & Dr John Reed (Oxford) |
| 07:50 – 07:55 | CSU and its effects on patients' lives
Dr Clive Grattan (London) & Dr John Reed (Oxford) |
| 07:55 – 08:10 | 2017 EAACI Guidelines: how can this help you and your patient
Dr Clive Grattan (London) & Dr John Reed (Oxford) |
| 08:10 – 08:25 | Objectively assessing CSU patients: PROMs
Dr Clive Grattan (London) & Dr John Reed (Oxford) |
| 08:25 – 08:30 | Audience Q&A
Dr Clive Grattan (London) & Dr John Reed (Oxford) |

Notes



Date: Wednesday 4th July
Time: 08:45 – 12:40
Room: Pentland
Chair: Dr Shikha Gupta & Dr Adam Fityan
 Dr Mike Ardern-Jones & Dr Giles Dunnill

Date: Wednesday 4th July
Time: 08:45 – 12:40
Room: Pentland
Chair: Dr Shikha Gupta & Dr Adam Fityan
 Dr Mike Ardern-Jones & Dr Giles Dunnill

08:45 – 09:00	O01	Timing of the last dose of biologic therapy and risk of postsurgical infections in patients with psoriasis <u>Z. Yiu</u>, D. Ashcroft, I. Evans, K. McElhone, S. Walton, M. Lunt, C. Griffiths and R. Warren
09:00 – 09:15	O02	Methotrexate for the treatment of adult atopic eczema: a two-centre, retrospective case note review of 161 patients with a focus on effectiveness and side-effect profile <u>G. Dhawan</u>, Y. Teo, W. Ghumra, F. Kreeshan, M.-L. Daly, S. Meggitt, A. Pink, N. Reynolds and C. Smith
09:15 – 09:45	MD01	From Balham to Burnley: Medical dermatology pearls from off the beaten track Dr Ian Coulson (Burnley)
09:45 – 10:00	O03	Epidemic of (meth)acrylate allergy in U.K. requires routine patch testing <u>S. Rolls</u>, S. Rajan, A. Shah, J. Bourke, M. Chowdhury, P. Cousen, A. M. Flynn, S. Ghaffar, C. Green, G. Johnston, K. Naido, D. Orton, E. Owen, C. Reckling, N. Stone, D. Thompson, S. Wakelin, M. Wilkinson and D. Buckley
10:00 – 10:15	O04	Antidrug antibodies in psoriasis patients during the first year of treatment with adalimumab/ ustekinumab: a multicentre prospective observational cohort study <u>T. Tsakok</u> and PSORT Consortium
10:15 – 11:00	Break	Exhibition Halls
11:00 – 11:30	MD02	Cutaneous amyloid Dr Richard Groves (London)
11:30 – 11:45	O05	Identification of clinical and immunological factors associated with clinical relapse in pemphigus patients within 9 months of study inclusion <u>A. Guliani</u>, D. De, S. Handa, R. Mahajan, N. Sachdeva and B.D. Radotra

Notes

British Cosmetic Dermatology Group

Date: Wednesday 4th July

Time: 08:45 – 12:30

Room: Moorfoot & Kilsyth

Chair: Dr Bav Shergill

Programme

08:45 – 09:00 BCGL1 Training pathways for cosmetic dermatology practice in the UK.
Dr Bav Shergill (Hove)

09:00 – 09:20 BCGL2 Topical treatments you need to know about
Dr Anjali Mahto (London)

09:20 – 09:40 BCGL3 Modern management of scars
Dr Emma Craythorne (London)

09:40 – 09:50 BCO1 Subcision – the all-rounder modality to enhance the efficacy of microneedling for acne scars. A prospective study of 45 patients at tertiary care centre
S. Bhargava, U. Kumar and K. Varma

09:50 – 10:10 BCGL4 Complications of cosmetic treatments
Dr Nis Sheth (London)

10:10 - 10:20 BC02 Filler-induced granulomatous reaction two-years after the treatment
M. Ebadian and A. Chapman

10:20 – 10:45 Break Exhibition Halls

10:45 – 11:15 BCGL5 Management of melasma and hyperpigmentation
Dr Rhonda Meys (Dubai, United Arab Emirates)

11.15 – 11:25 BC03 Decoding periorbital dark circles!
A. Pandya and S. Rajpara

11.25 - 11.50 BCLG6 Lessons from running an independent practice
Dr Russel Emerson (Sussex)

11:50 – 12:00 Questions and Discussion

12:00 – 12:30 AGM

Posters

BG04 Aesthetic and health concerns with sex hormone decline age
A. Chapman

BG05 Pyoderma gangrenosum triggered by a decorative tattoo
S. Hadjieconomou and N. Stone

BG06 Randomized, controlled, split-face study of combination therapy with topical methimazole plus low-power fractional CO2 laser vs. topical methimazole plus Q-switch laser for treatment of melasma
G.R. Rokni and M.G. Jouybari

BG07 Unreported granulomatous cutaneous reaction after 'top up tan' (melanotan) injections
K.S. Mukkanna, P. Srivastava and M. Kalavala

BG08 Cryotherapy vs. CO2 laser therapy in the treatment of plantar warts: a randomized clinical trial
F. Handjani and N. Hemmatian

The poster viewing session will take place during the lunch break on the Wednesday 4th July

Notes

Date: Wednesday 4th July
Time: 09:00-12:30
Room: Sidlaw
Chair: Prof Edel O'Toole
Prof Sara Brown



09:00 – 09:05		Welcome Prof Edel O'Toole
09:05 – 09:15	BG01	Novel <i>ADAR</i> mutations in two cases of dyschromatosis symmetrica hereditaria <u>S. O'Sullivan</u>, S.M. Lwin, L. Liu, J. Lai-Cheong, J.A. McGrath and J.E. Mellerio
09:15 – 09:25	BG02	Mosaic <i>SMO</i> mutation in a patient with linear basal follicular hamartomas confirms Happle-Tinschert syndrome as a variant of Curry-Jones syndrome <u>M.-L. Lovgren</u>, S.R.F. Twigg and C. Moss
09:25 – 09:35	BG03	Congenital rhabdomyosarcoma associated with phakomatosis pigmentokeratotica and mosaic RASopathy <u>N. Harper</u>, C. Moss, D. Lim, P. Rehal, M. Munir and M. Ogboli
09:35 – 09:45	BG04	Distinct phacomatosis pigmentokeratotica phenotypes in two mosaic HRAS mutation carriers: a question of timing? <u>A. Shah</u>, B. Monk, M. Arefi, C. Moss and N. Rajan
09:45 – 10:10		Invited Talk: An update on primary lymphoedema Dr Kristiana Gordon (London)
10:10 – 11:00	Break	Exhibition Halls
11:00 – 11:25		Invited Talk: Alopecia, hypotrichosis and uncombable hair syndrome: when to think of genetic testing? Prof Regina Betz (Bonn, Germany)
11:25 – 11:35	BG05	Heterozygous mutations in AAGAB causing punctate palmoplantar keratoderma associated with plantar pain <u>A. Randhawa</u>, F.J.D. Smith, N.J. Wilson, A. Mackenzie, G.J. Sobey and M. Zamiri

11:35 – 11:45	BG06	Phenotypic spectrum of 146 cases of autosomal recessive congenital ichthyosis in England <u>J. Simpson</u>, M. Martinez-Queipo, A. Onoufriadis, S. Tso, E. Glass, L. Liu, T. Higashino, W. Scott, C. Tierney, M. Simpson, L. Youssefian, A. Saedian, H. Vahnidnezhad, A. Bisquera, J. Mellerio, A. Martinez, C. Moss, E. O'Toole, N. Burrows, J. Ravenscroft, S. Leech, E. Jones, D. Lim, A. Ilchyshyn, N. Goldstraw, M. Cork, S. Darne, J. Uitto and J. McGrath
11:45 – 12:10		Invited talk: Tuberous sclerosis: diagnosis, treatment and prevention Prof Julian Sampson (Cardiff)
12:10 – 12:20	BG07	Basaloid follicular proliferations and brain tumours: the tumour spectrum of <i>SUFU</i> mutation carriers <u>S. Manam</u>, T. Oliphant, A. Henderson, A. Husain and N. Rajan
12:20 – 12:30		BADGEM Initiatives Dr Neil Rajan (Newcastle)

Posters

- BG08 Erdheim–Chester disease, malignant melanoma and papillary thyroid cancer on a background of mosaic Turner syndrome: is there a shared link?
T. Chohan, M. Papanikolaou and G. Millington
- BG09 PLACK syndrome: the penny dropped
S. O’Sullivan, C. McDonald, L. Liu, J.A. McGrath, J.E. Mellerio and A.E. Martinez
- BG10 Abstract withdrawn
- BG11 Novel mutations in desmoglein 1: focal palmoplantar keratoderma in milder phenotypes
E.V. Wray, N.J. Wilson, E. O’Toole, F. Smith and M. Zamir
- BG12 Pigmentary anomaly caused by mosaic dup (3) (q22.2q29)
B.S. M-Falero and H. Lotery
- BG13 Fragile fissuring genital skin associated with Ehlers Danlos syndrome
E. O’Brennan, K. Eustace, J. Scanlon and H. Bell
- BG14 Papular naevus spilus syndrome
D. Torchia
- BG15 22q11.2 duplication syndrome
J. Denny, N. Valiallah and J. Natkunarajah

The poster viewing session will take place during the lunch break on Wednesday 4th July

Notes

Sponsored Symposium: Janssen

Date: Wednesday 4th July
Time: 13:00 – 14:00
Room: Sidlaw
Chair: Prof Chris Griffiths & Dr Jenny Hughes



Programme

Emerging data for guselkumab and other IL-23 inhibitors in psoriasis:
From data to clinical application

- 13:00 – 13:10** Welcome
Prof Chris Griffiths (Manchester) & Dr Jenny Hughes (Bridgend)
- 13:10 – 13:30** IL-23 in psoriasis
Prof Chris Griffiths (Manchester)
- 13:30 – 13:55** Panel discussion and audience Q&A
- 13:55 – 14:00** Summary and close
Dr Jenny Hughes (Bridgend)

Notes

Sponsored Symposium: UCB Pharma

Date: Wednesday 4th July
Time: 13:00 – 14:00
Room: Fintry
Chair: Prof Jonathan Barker



Programme

Making patient-centric choices when treating severe psoriasis in women of child bearing age

- | | |
|----------------------|---|
| 13:00 – 13:05 | Welcome and Introduction |
| 13:05 – 13:15 | Biologics in Pregnancy
Dr Kenneth Hodson (Consultant in Obstetrics and Maternal Medicine, Newcastle upon Tyne Hospitals NHS Trust) |
| 13:15 – 13:25 | Guidelines and Real World Evidence
Prof Nick Reynolds (Consultant Dermatologist, Newcastle upon Tyne Hospitals NHS Trust) |
| 13:25 – 13:35 | Case Studies and Real World Experience
Prof Caitriona Ryan (Consultant Dermatologist and Clinical Assistant Professor, University College Dublin) |
| 13:35 – 14:00 | Panel discussion |

Notes

Sponsored Symposium: Sanofi Genzyme

Date: Wednesday 4th July
Time: 13:00 – 14:00
Room: Moorfoot & Kilsyth
Chair: Prof Michael Cork



Programme

From target to treatment: A new era in Atopic Dermatitis

- | | |
|----------------------|---|
| 13:00 – 13:10 | Welcome & Introduction
Prof Michael Cork (Sheffield) |
| 13:10 – 13:30 | Evolving therapies in atopic dermatitis: clinical trials and real world insights
Prof Diamant Thaci (Lübeck, Germany) |
| 13:30 – 13:50 | What's the score with Atopic Dermatitis? Early experience with Dupixent ▼ (Dupilumab)
Dr Andrew Pink (London) |
| 13:50 – 14:00 | Discussion
Prof Michael Cork (Sheffield) |

This symposium is organised and funded by Sanofi Genzyme.

Sanofi Genzyme and Regeneron are committed to providing resources to advance research in dermatology in areas of unmet medical needs among patients with poorly controlled moderate-to-severe atopic dermatitis.

SAGB.DUP.18.03.0402 March 2018

Notes

Plenary Session - Submitted Papers

Date: Wednesday 4th July
Time: 14:00 – 15:15
Room: Pentland
Chair: Dr Tanya Bleiker & Dr Jui Vyas

Programme

- 14:00 – 14:15

BMJ Dermatology Team of the Year award: Social enterprise- a 21st Century paradigm for delivering dermatology in secondary care
F.R. Ali, J. Ayer, L. Black, N.J. Gathercole, W. Maxwell, J. O’Driscoll, V. Ramsden, R. Stones, T.W. Griffiths, T.P. Kingston
Vernova Community Interest Company, Macclesfield
- 14:15 – 14:30

O07 A 10-year prospective longitudinal follow-up study of a U.K. paediatric transplant population to assess for skin cancer
S.H. Foo, P. Nightingale, P. Gazzani, E. Bader, M. Ogboli, A. Martin-Clavijo, D. Milford, D. Kelly, C. Moss and M. Thomson
- 14:30 – 14:45

O08 Efficacy of a topical Hedgehog inhibitor for treatment and prevention of BCC in Gorlin syndrome: a phase II randomized controlled trial of topical patidegib
J. Lear, E. Epstein, J. Tang and C. Harwood
- 14:45 – 15:00

O09 What is the true burden of skin cancer? Recent trends in incidence of nonmelanoma skin cancers in Northern Ireland
A. Alani, C. Mc Court, E. Morgan, D. Fitzpatrick, A. Gavin and O. Dolan
- 15:00 – 15:15

O10 Evaluation of effectiveness and safety of P-32/Re-188 incorporated radioactive skin patches for treatment of basal cell carcinoma
K. Verma, P Gupta, R. Kumar, P. Kumar and C.S. Bal

Notes

British Society for Investigative Dermatology

Date: Wednesday 4th July
Time: 14:00 -15:30
Room: Carrick
Chair: Dr Helen Young, Dr Daniele Bergamaschi & Prof Des Tobin

Programme

- 14:00 – 14:10

Best Presentation from the BSID Annual Meeting
Loss of Lama3 drives M2 Macrophage differentiation in squamous cell carcinoma
Dr Matthew Caley (London)
- 14:10 – 14:40

Epidermal Barrier - Structural and Immune aspects
Dr Ryan O-Shaughnessy (London)
- 14:40 – 14:50

Best Presentation (PhD student) from the BSID Annual Meeting
Investigating the role of ABCA12 in the Pathomechanisms of Harlequin Ichthyosis
Ms Florence Enjalbert (London)
- 14:50 – 15:00

Best Young Investigator Award 2018 Recipient
iRHOM2 signalling in the keratinocyte stress response
Dr Anissa Chikh (London)
- 15:00 – 15:30

From DNA to functional effect: what can genetic studies teach us about eczema?
Prof Sara Brown (Dundee)

Notes

British Teledermatology Society

Date: Wednesday 4th July
Time: 14:15 – 16:15
Room: Fintry
Chair: Dr Saul Halpern

Programme

14:15 – 14:20		Welcome Introduction - Teledermatology 2018 Dr Saul Halpern
14:20 – 14:40		Artificial Intelligence in Dermatology; friend or foe? Dr Colin Morton (Stirling)
14:40 – 14:50	BT01	The advantage of teledermoscopy in the early detection of amelanotic/hypomelanotic melanoma A. Atwan and C. Mills
14:50 – 15:00	BT02	The facts, figures and tribulations of a new teledermatology service: an update on the pilot study presented at the 97th British Association of Dermatologists annual meeting L. Thomas, A. King, C. Fuller and C. Macedo
15:00 – 15:10	BT03	The evaluation of ‘hospital to book to 2-week-wait clinic’ option in teledermatology F. Xie and D. de Berker
15:10 – 15:20	BT04	NHS e-referral ‘advice and guidance’ teledermatology: experience from 6000 referrals C. Charman, A. Walker, R. Batchelor, P. Williams, N. Goldstraw and H. Frow
15:20 – 15:30	BT05	Is teledermatology a reliable triage service for skin lesions? F. Xie, G. Osborne, J. Sansom, D. Shipley, P. Bogucki and D. de Berker
15:30 – 15:40	BT06	Does GP experience of primary care-based teledermatology influence their usage pattern? A comparison of two CCG areas using the KYSOS teledermatology platform Z. Hasan, A. Opoola and S. Halpern
15:40 – 15:50	BT07	How do you provide remote dermatology on-call support to peripheral hospitals? A. Banner, D. de Berker, B. Hawthorne, K. Curtis and J. Macdonald
15:50 – 16:00	BT08	Use of dermatology apps: a cause for concern or the future of healthcare provision? M. Charalambides and S. Singh
16:00 - 16:15		AGM



Psychodermatology UK

Date: Wednesday 4th July
Time: 14:15 – 17:15
Room: Sidlaw
Chair: Dr Andrew Affleck & Dr Alia Ahmed
Dr Janet Angus & Dr Susannah Baron

Programme

14:15 – 14:40	PSGL1	Guest Lecture Psoriasis: The skin, the brain and the invisible Dr Elise Kleyn (Manchester)
14:40 – 14:55	PS01	Efficacy of a mindfulness-based stress reduction intervention in chronic skin disease: a follow-up study from a cohort of Irish patients attending a dermatology service C. Broderick, J. Wilson-O’Raghallaigh, L. Murphy, E. Moran, L. Power, M. Cannon and M. O’Kane
14:55 – 15:05	PS02	The risk of depression and anxiety in adults diagnosed with vitiligo compared with the general population in the U.K. S. Ratib, L. Ban, M. Santer, A. Thompsom, A. Ahmed, M. Grainge, C. Crooks and J. Batchelor
15:05 - 15:15	PS03	Diagnosis and management of psychodermatological problems: confidence levels among dermatologists and psychiatrists V. Muralidharan, D. Zahedi, B. Kaur and J.M.R. Goulding
15:15 – 15:25	PS04	The psychological burden of skin disease in adult dermatology outpatients K. Lockwood, A. Al Haddabi and S. Weatherhead
15:25 – 16:05	Break	Exhibition Halls
16:05 – 16:15	PS06	The role of U.K. dermatology patient support groups E. McNulty-Brown, W.A. Woo and S. George
16:15 – 16:25	PS07	Use of psychiatric medications in Scottish dermatology departments: a survey and educational summary of current practice S. Ball, C. Howes, M. Farrugia, N. Salmon and W. Wojcik
16:25 – 16:35	PS08	Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients and those with more extensive skin involvement K. Molloy, C. Peng, R. Cowan, E. Parry, A. Busschots, E. Hauben, M. Bayne, A. Bates, K. Benstead, J. Yoo, C. Jonak and J. Scarisbrick
16:35 – 16:45	PS09	To what extent do clinicians’ (disease severity) and patients’ (illness perceptions) ratings of disease explain depression, anxiety and quality of life in hidradenitis suppurativa A. Pavon Blanco, M. Turner, J. Weinman and G. Petrof



Notes

PS13 A review of dermatology referrals to liaison psychiatry services
L. Power, M. Cannon and M. O'Kane

PS14 Psychological comorbidity of the photodermatoses: a review
I. Ashraf and L. Rhodes

PS15 Rosacea remedies influenced by Internet forums
A. Affleck and L. Riddoch

PS16 Nonattendance in the psychodermatology clinic: strategies for improvement
J. Coe, M. Patel, C. Muller-Pollard, S.M.C. George, J.M.R. Goulding and J. Felton

PS17 Focus group evaluation of www.skincareuk.org: a website developed by the British Association of Dermatologists
A. Thompson, K. Montgomery, N. Goad, M. Gass and S. Ersser

PS18 Atypical trigeminal trophic syndrome
J. Denny, N. Valiallah and J. Natkunarajah

PS19 Internet-influenced self-treatment of skin cancer with alternative therapy
D. Jackson and A. Affleck

PS20 Prospective study of the impact of phototherapy in patients with psoriasis on: mood, quality of life, well-being, itch and fatigue
C. Cotter, A. Marie Tobin, R. O'Connor, C. Gallagher, M. Connolly and A. Salim

The poster viewing session will take place during the lunch break on Wednesday 4th July

Notes

Historical Symposium

Date: Wednesday 4th July
Time: 14:15 – 15:30
Room: Tinto
Chair: Dr Nick Levell

Programme

14:15 – 14:27	H01	Thomas Addison: the dermatologist <u>S. Austin</u>, <u>S. Babu</u>, <u>A. Macklin</u>, <u>C. Grossmith</u> and <u>S. Taibjee</u>
14:27 – 14:39	H02	A stitch in time: from flax and biting ants to the first synthetic suture <u>N. King</u> and <u>A. Abdullah</u>
14:39 – 14:51	H03	Pellagra: the a-maize-ing history <u>T.S. Chohan</u>, <u>R.S. Chohan</u> and <u>N.J. Levell</u>
14:51 – 15:03	H04	Blistering since before one can remember: the epidermolysis bullosa story <u>A. Bardhan</u> and <u>A. Heagerty</u>
15:03 – 15:30	HGL	Guest Lecture Scottish Photodermatology and its historical context Prof James Ferguson (Dundee) Please join us after the session finishes to share some Madeira wine and cake in celebration of Robert Willan

Notes



Posters

H05	Robin Eady: the extraordinary life and achievements of a remarkable man <u>G. Petrof</u> and <u>F. Humphreys</u>
H06	Bald's Leechbook:- 'the first English writings on Dermatology' <u>D. Ondhia</u> and <u>N. Levell</u>
H07	Parchment skin, the origins of xeroderma pigmentosum <u>P. Patel</u> and <u>G. Millington</u>
H08	Caterpillars, chemists and contact dermatitis: a history of patch testing <u>S. Holloron</u>, <u>T. Finch</u> and <u>S. Orpin</u>
H09	Of insects and itching: the illustrious career of John O'Donel Alexander (1915–2003) <u>I. Kreuser-Genis</u> and <u>C. Clark</u>
H10	Professor Stefania Jabloska: bridging the political divide through dermatology <u>A. Livesey</u> and <u>A. Shipman</u>
H11	Uncovering the history of medical camouflage <u>N. King</u> and <u>A. Abdullah</u>
H12	Dr. Walter Fredrick Lever (1909–1993) – Dermatopathologist and forefather of bullous pemphigoid <u>A. Shah</u> and <u>K. Harman</u>
H13	Freckling and caf_e-au-lait macules; Friedrich Daniel von Recklinghausen (1833–1910), the man who unveiled NF1 <u>L. Brindley</u>, and <u>M. Paul</u>
H14	'I can't believe this is history' – dithranol for severe psoriasis <u>A. Kelly</u>, <u>S. Rogers</u> and <u>B. Kirby</u>
H15	A visit to Sungai Buloh Leprosarium 'The Valley of Hope': exploring its fascinating history <u>R. Jerrom</u>, <u>D. Jackson</u>, <u>A. Gan</u> and <u>A.T. Gan</u>
H16	Excision with precision: dissecting the layers of history beneath Mohs micrographic surgery <u>K. Dear</u> and <u>E. Benson</u>
H17	A brief history of the dermatoscope <u>R. Jones</u>
H18	Sophie Spitz: mother of the masquerading mole <u>E. Blakeway</u> and <u>A. Mitra</u>
H19	GA Grant Peterkin: a pillar of Edinburgh dermatology <u>D. Tabor</u>
H20	Alan Lyell – one of the founding fathers of modern dermatology <u>G. Petrof</u> and <u>F. Humphreys</u>
H21	Dapsone over the years: from fabric dye to the master of pharmaceutical re-invention <u>A. Shah</u>, <u>M. Ali</u> and <u>B. Monk</u>



- | | |
|-----|---|
| H22 | Malariotherapy to treat cutaneous diseases
A. Shipman and N. Huntington |
| H23 | The sun and the skin: waves of change in photoprotection
N. Gopee, S. Tariq and N. Levell |
| H24 | Disfigurement as public entertainment in the circus side-shows of 18th and 19th centuries Britain
D.J. Gawkrödger |

The poster viewing session will take place during the lunch break on Wednesday 4th July

Please remember to go and visit the BAD stand located in the Atrium to see our historical display

Notes

Plenary Session – Melanoma MDT

Date: Wednesday 4th July
Time: 16:00-18:00
Room: Pentalnd
Chair: Dr Raj Mallipeddi & Dr Louise Fearfield

Programme

16:00 – 16:30 **Keynote Lecture** - Introduced by **Dr Tanya Bleiker**
Therapeutic checkmate in melanoma
Prof Hensin Tsao (Boston, USA)



Not less than 5 years ago, there was tremendous excitement about BRAF inhibitors, molecular testing and targeted therapies. Fast forward a few trials and the melanoma world is ablaze with checkpoint inhibitors. Is it finally checkmate for advanced melanoma? For the first time in the history of melanoma therapeutics, clinicians are finally whispering the “C” word- “cure”- to their patients. This talk will describe the latest breakthroughs in the treatment of stage III and IV melanoma.

16:30 – 16:50 **Invited Lecture**
The Skin Cancer MDT
Prof Martin Gore, Consultant Medical Oncologist (London)

16:50 – 17:10 **Invited Lecture**
Early Diagnosis
Dr Catriona Henderson, Consultant Dermatologist (Southampton)

17:10 - 17:20 Invited Lecture
Melanoma Staging
Mr Jonathan Pollock, Consultant Plastic Surgeon (Nottingham)

17:20 – 17:40 **Invited Lecture**
Patient Experience/ Survivorship
Peta Hughes CNS (London)

17:40 – 18:00 **Invited Lecture**
Melanoma Surgery - Are current margins too large?
Mr Andy Hayes, Consultant Surgeon (London)

UK TREND - Clinical and translational research in Keratinocyte Cancer

Date: Wednesday 4th July
Time: 16:30-18:00
Room: Tinto
Chair: Prof Eugene Healy & Prof Irene Leigh



Programme

- 16:30 – 16:35** Introduction and welcome to UK TREND
- 16:35 – 16:55** Keratinocyte carcinoma incidence in the UK
Dr Zoe Venables (Leicester)
- 16:55 – 17:15** Molecular mechanisms of cutaneous squamous cell carcinoma development
Prof Catherine Harwood (London)
- 17:15 – 17:35** Cutaneous squamous cell carcinoma immunity
Dr Chester Lai (Southampton)
- 17:35 – 17:55** Tweets, Teens and Tanning beds: Using technology for skin cancer prevention
Dr Eleni Linos (San Francisco, USA)
- 17:55 – 18:00** Closing remarks

Notes

Sponsored Symposium: Celgene

Date: Wednesday 4th July
Time: 18:15 – 19:00
Room: Sidlaw
Chair: Dr Michael Mosley



Programme

What does real world experience tell us about how patients define treatment success?


Confirmed Speakers:

- Dr Michael Mosley**, TV science presenter and writer
- Dr Kave Shams**, Consultant Dermatologist, St James' University Hospital, Leeds
- 18:15 – 18:20** Welcome and introduction
- 18:20 – 18:30** Psoriasis management: a changing approach
- 18:30 – 18:40** Real world experience of psoriasis patients treated with Otezla®▼ (apremilast): APPRECIATE
- Study design and methodology
- 18:40 – 18:50** UK and Ireland: Results from the APPRECIATE study
- 18:50 – 19:00** Panel discussion and closing comments

Notes

Sponsored Symposium: LEO Pharma UK

Date: Wednesday 4th July
Time: 18:15 – 19:00
Room: Fintry
Chair: Prof Richard Warren



Programme

The psoriasis treatment revolution: Experience from the real world

- 18:15-18:20** Welcome, introduction and summary of the evolving new order in systemic plaque psoriasis treatment
Prof Richard Warren (Salford Royal NHS Foundation Trust and The University of Manchester)
- 18:20-18:35** All clear: A new frontier in plaque psoriasis treatment goals
Dr Kim Papp (Clinical Research and Probiy Medical Research, Waterloo, Ontario)
- 18:35-18:50** Seeing the real difference: Insights from real-world experience
Prof Marc Alexander Radtke (University Medical Center of Hamburg-Eppendorf)
- 18:50-19:00** Panel discussion and audience Q&A

Abbreviated Prescribing Information for Kyntheum® (brodalumab) 210 mg solution for injection in pre-filled syringe

Please refer to the full Summary of Product Characteristics (SmPC) (www.medicines.org.uk/emc) before prescribing.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Indication: Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.

Active ingredient: Each pre-filled syringe contains 210 mg brodalumab in 1.5 ml solution. 1 ml solution contains 140 mg brodalumab.

Dosage and administration: Posology: Adults: The recommended dose is 210 mg administered by subcutaneous injection at weeks 0, 1, and 2 followed by 210 mg every 2 weeks. Consideration should be given to discontinuing treatment in patients who have shown no response after 12-16 weeks of treatment. Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks. Administer by subcutaneous (SC) injection. Each pre-filled syringe is for single use only. Elderly: No dose adjustment recommended. Hepatic and renal impairment: No dose recommendations can be made. Children and adolescents below the age of 18 years: Safety and efficacy of Kyntheum have not been established. Method of administration: Kyntheum should not be injected into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis. The pre-filled syringe must not be shaken. After proper training in SC injection technique, patients may self-inject Kyntheum when deemed appropriate by a physician. Patients should be instructed to inject the full amount of Kyntheum according to the instructions provided in the package leaflet.

Contraindications: Hypersensitivity to the active substance or to any of the excipients. Active Crohn's disease. Clinically important active infections (e.g. active tuberculosis).

Precautions and warnings: *Crohn's disease:* Exercise caution when prescribing Kyntheum to patients with a history of Crohn's disease. They should be followed for signs and symptoms of active Crohn's disease. If

patients develop active Crohn's disease, treatment should be discontinued permanently. *Suicidal ideation and behaviour:* A causal association between treatment with Kyntheum and increased risk of suicidal ideation and behaviour has not been established. Carefully weigh the risk and benefit of treatment with Kyntheum for patients with a history of depression and/or suicidal ideation or behaviour, or patients who develop such symptoms. Patients, caregivers and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal ideation, anxiety, or other mood changes, and they should contact their healthcare provider if such events occur. If a patient suffers from new or worsening symptoms of depression and/or suicidal ideation or behaviour is identified, it is recommended to discontinue treatment with Kyntheum. *Infections:* Kyntheum may increase the risk of infections. Caution should be exercised when considering the use of Kyntheum in patients with a chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, they should be closely monitored and Kyntheum should not be administered until the infection resolves. Kyntheum should not be given to patients with active tuberculosis. Anti-tuberculosis therapy should be considered prior to initiation of Kyntheum in patients with latent tuberculosis. *Reduced absolute neutrophil count:* A decrease in absolute neutrophil count, generally transient and reversible, has been observed in 5.6% of patients receiving Kyntheum. *Vaccinations:* It is recommended that patients be brought up-to-date with all immunisations in accordance with local immunisation guidelines prior to initiation of treatment with Kyntheum. Live vaccines should not be given concurrently with Kyntheum. The safety and efficacy of Kyntheum in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated.

Drug interactions: Live vaccines should not be given concurrently with Kyntheum.

Fertility, pregnancy and lactation: *Women of childbearing potential:* Use an effective method of contraception during treatment and for at least 12 weeks after treatment. *Pregnancy:* There are no or limited amount of data from the use of brodalumab in pregnant women. As a precautionary measure, it is preferable to avoid the use of Kyntheum in pregnancy. Benefit risk for exposure of the infant to live vaccines following third

trimester exposure to Kyntheum should be discussed with a physician. *Breast-feeding:* It is unknown whether brodalumab is excreted in human milk. A risk to the newborns/infants cannot be excluded. Whether to discontinue breast-feeding or discontinue Kyntheum therapy should be decided, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. *Fertility:* No data are available on the effect of brodalumab on human fertility.

Side effects: *Common (≥1/100 to <1/10):* Influenza, tinea infections (including tinea pedis, tinea versicolor, tinea cruris), neutropenia, headache, oropharyngeal pain, diarrhoea, nausea, arthralgia, myalgia, fatigue, injection site reactions (including injection site erythema, pain, pruritus, bruising, haemorrhage). *Uncommon (≥1/1,000 to <1/100):* Candida infections (including oral, genital and oesophageal infections), conjunctivitis.

See SmPC for a full list of side effects.

Precautions for storage: Store in a refrigerator (2°C-8°C). Do not freeze. Keep the pre-filled syringe in the outer carton in order to protect from light. Kyntheum may be stored at room temperature (up to 25°C) once, in the outer carton, for a maximum single period of 14 days. Once Kyntheum has been removed from the refrigerator and has reached room temperature (up to 25°C) it must either be used within 14 days or discarded.

Legal category: POM.

Marketing authorisation number and holder: EU/1/16/1155/001, LEO Pharma A/S, Ballerup, Denmark.

Basic NHS price: 2 pre-filled syringes: £1,280 (each syringe contains 210 mg/1.5 ml).

Last revised: March 2018

Further information can be found in the Summary of Product Characteristics or from: LEO Pharma, Horizon, Honey Lane, Hurley, Berkshire SL6 6RJ. e-mail: medical-info.uk@leo-pharma.com

Reporting of Suspected Adverse Reactions: Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google Play or Apple Store.

Adverse events should also be reported to Drug Safety at LEO Pharma by calling +44 (0)1844 347333 or e-mail medical-info.uk@leo-pharma.com

© Registered trademark



FREZYDERM ac-norm

AN ALTERNATIVE TREATMENT APPROACH FOR ACNE-PRONE SKIN

Innovation

medilike proposal

Active ingredients with comparable effectiveness to pharmaceutical actives

- / biomimesis of topical retinoids
- / biomimesis of topical antibiotics
- / biomimesis of azelaic acid

No side effects

Innovation

OPTIMIZED DELIVERY Technology

Increased percutaneous absorption of active ingredients

- / osmotically controlled release of active ingredients
- / immediate result

Suitable for teenagers, pregnant and breastfeeding women

AUTONOMOUS TREATMENT | SYNERGY WITH MEDICAL TREATMENTS | NON - COMEDOGENIC | PARABEN-FREE

Looking for impartial, expert advice on acne?

Visit www.acnesupport.org.uk

Brought to you by the British Association of Dermatologists

acnesupport Proudly sponsored by
 Offering you impartial, expert advice on acne FREZYDERM

Time	Session Detail	Room	Page
07:45 – 08:30	Almirall Sponsored Symposium	Tinto	69
07:45 – 08:30	Lilly Sponsored Symposium	Kilsyth	70
08:30 – 12:15	Professors & Registrars Session	Pentland	71
08:30 – 12:15	BSPD & BSPAR joint session	Sidlaw	72
08:30 – 12:15	British Photodermatology Group	Fintry	76
10:15 – 10:45	Hot Topics	Exhibition Halls	86
10:15 – 10:45	Poster Walks	Mezzanine Level	88
10:30 – 12:30	British Hair & Nail Society	Moorfoot & Kilsyth	79
12:15 – 12:45	Lunchtime Journal Club	Lennox Hall	87
13:00 – 14:15	Plenary Session - Tropical Disease	Pentland	81
14:15 – 14:30	Presidents Address	Pentland	81
14:30 – 15:15	Arthur Rook Oration: Prof Hywel Williams	Pentland	81
15:30 – 17:00	Dermoscopy update teaching session	Sidlaw	82
15:30 – 17:00	Advanced Medical Dermatology: Challenging cases. An interactive session	Fintry	83
15:30 – 17:00	Health service delivery, management research and GIRFT symposium	Tinto	84

Sponsored Symposium: Almirall

Date: Thursday 5th July
Time: 07:45 – 08:30
Room: Tinto
Chair: Prof Colin Fleming



Programme

A management dilemma: Moderate Psoriasis

Summary: A debate on how to define, treat and manage “moderate” psoriatic patients

Confirmed Faculty: **Prof Colin Fleming (Dundee)**
Dr Sandy McBride (London)
Prof Kave Shams (Leeds)

07:45 – 07:55 Welcome and introducing current debate in treating moderate psoriatic patients

07:55 – 08:10 For: Is psoriasis only skin deep?

08:10 – 08:25 Against: Timing is everything!

08:25 – 08:30 Voting and Close

Notes

Sponsored Symposium: Lilly

Date: Thursday 5th July
Time: 07:45 – 08:30
Room: Kilsyth



Programme

Desert Island Dermatology

Interviewer: **Dr Joyce Leman (Consultant Dermatologist, Victoria Hospital, Kirkcaldy)**

Castaway: **Dr Ian Coulson (Consultant Dermatologist, Burnley General Hospital)**

07:45 – 08:30 Join us to hear Dr Ian Coulson as he discusses the key moments that have impacted his clinical practice throughout his career in dermatology

PP-IX-GB-0319 April 2018

Notes

Professors & Registrars Session

Date: Thursday 5th July
Time: 08:30 – 12:15
Room: Pentland
Chair: Dr Mabs Chowdhury & Dr Amr Salam
 Dr Mike Ardern-Jones & Dr Eugene Ong

Programme

08:30 – 08:45	RF01	Cutaneous sarcoidosis: clinical spectrum in a tertiary referral centre <u>A. Paolino</u> and S. Walsh
08:45 – 09:00	RF02	Post-transplant skin cancer incidence has halved, for both BCC and SCC, since the turn of the century <u>S. Menzies</u>, E. O’Leary, S. Deady, G. Callaghan, C. MacEochagain, B. Gadallah, P. Lenane, A. Lally, D. Houlihan, P.G. Morris, D. Sexton, A. McCormick, J.J. Egan, J.P. O’Neill, P.J. Conlon and F.J. Moloney
09:00 – 09:20	PR01	Key Issues in cutaneous Squamous Cell Carcinoma Prof Charlotte Proby (Dundee)
09:20 – 09:35	RF03	Challenging our view on mutations in female genital melanoma: should they be grouped together? Experience from a supra-regional melanoma centre <u>A. Wernham</u>, P. Taniere, M. Evans and S. Velangi
09:35 – 09:50	RF04	The virtual systemic monitoring clinic <u>N. Alwash</u>, M. Patel and C. Degiovanni
09:50 – 10:45	Break	Exhibition Halls
10:45 – 11:00	RF05	Clive Archer THESIS Fellowship 2018 Winner Allogeneic cell-based therapies for individuals with recessive dystrophic epidermolysis bullosa Dr Gabriela Petrof (London)
11:00 – 11:20	PR02	The optimisation of therapies for the treatment of psoriasis Prof Richard Warren (Manchester)
11:20 – 11:35	RF06	BSID best registrar paper Exome sequencing of cohort of actinic keratoses to identify significantly mutated genes Dr Jason Thomson (London)
11:35 – 11:55	PR03	Understanding eczema from different perspectives Prof Sara Brown (Dundee)
11:55 – 12:15	PR04	Clinical immunology of the human hair follicle Prof Ralf Paus (Manchester)

British Society for Paediatric Dermatology & British
Society of Paediatric & Adolescent Rheumatology

Date: Thursday 5th July

Time: 08:30 – 12:15

Room: Sidlaw

Chair: Dr Tess McPherson & Dr Karolina Gholam
Dr Lindsay Shaw & Dr Jacqui Clinch

Programme

08:30 – 08:40	PA01	Consensus agreed diagnostic criteria for psoriasis in children: an eDelphi study with the International Psoriasis Council <u>E. Burden-Teh</u>, K. Thomas, S. Ratib and R. Murphy
08:40 – 08:50	PA02	Does moderate-to-severe eczema in children cause significant emotional distress, anxiety and depression as well as impact on children and their families quality of life? <u>J. Bracey</u>, S. Maynard, F. Meynall, C. Flohr, Z. Jabbar-Lopez and S. Baron
08:50 – 09:00	PA03	A 3-year review of paediatric patch testing <u>S. Khan</u>, F. Campbell, F. Macdonald and C. Jury
09:00 – 09:10	PA04	Paediatric vulval lichen sclerosis: a case series <u>D. Ismail</u> and C.M. Owen
09:10 – 09:20	PA05	Establishing and developing a novel teenage and young adult dermatology clinic: a model for developmentally appropriate skin health care <u>G. Wali</u>, R.M. Fisher and T. McPherson
09:20 – 09:30	PA06	Developmental influences and the risk of atopic eczema during infancy <u>S. El-Heis</u>, S. Crozier, E. Healy, S. Robinson, N. Harvey, J. Baird, H. Inskip, C. Cooper and K. Godfrey
09:30 – 10:00		Guest Lecture The role of the Paediatric Dermatologist in the diagnosis and management of Connective Tissue Disease - Lessons learned from a combined approach Dr Ruth Murphy (Sheffield)
10:00 – 10:45	Break	Exhibition Halls
10:45 – 11:10		Guest Lecture Bendy, in pain, tired, with a scar and bruises...is this Ehlers Danlos Syndrome? Dr Jacqui Clinch (Bristol)

11:10 – 11:35		Guest Lecture Bechets Disease Dr Clare Pain (Liverpool)
11:35 – 11:45	PA07	A severe case of eosinophilic fasciitis highlighting the challenges of managing a disengaged adolescent with multiple comorbidities <u>M. Lakhan</u>, S. Weston, K. Semkova, V. Shivamurthy, N. Wilkinson, E. Wedgeworth and S. Baron
11:45 – 11:55	PA08	Management of psoriasis during pregnancy: two cases of infliximab use and a review of safety evidence of systemic medications <u>J.M. Gao</u>, L. Ferguson and N. Roberts
11:55 – 12:05	PA09	A case of unilateral linear facial morphea, uveitis and brain involvement in a 2-year-old child treated with methotrexate <u>C. Peng</u>, N. Harper and J.E. Gach
12:05 – 12:15	PA10	Neonatal lupus erythematosus associated with ribonucleoprotein antibodies presenting as lip ulceration <u>M.-L. Lovgren</u> and P.E. Beattie

Notes

- PA11 Reclassification of facial port-wine stains according to embryonic vasculature and risk of Sturge-Weber Syndrome
G. Wali and T. McPherson
- PA12 Photosensitivity and low vitamin D status in children
L. Asfour and L Rhodes
- PA13 Treatment of paediatric atopic dermatitis with narrowband ultraviolet B phototherapy: a referral centre's experience
M. Hunjan, J. Brockley and R. Ramesh
- PA14 Keratitis-ichthyosis-deafness (KID) syndrome associated with Dandy-Walker malformation (DWM) suggesting dual role for *GJB2* gene
R. Ramessur, K. Batta and C. Allen
- PA15 An audit of the 'You're Welcome Criteria' in a paediatric dermatology department
E. Howard and S. Khara
- PA16 Abstract withdrawn
- PA17 A mixed presentation of sclerotic skin disease in a neonate
C. Haddadeen, M. Glover and B. Hughes
- PA18 Can we predict the chronology of oesophageal strictures in paediatric epidermolysis bullosa patients? A prospective study of 75 children
C. McDonald, D. Roebuck, J. Mellerio and A. Martinez
- PA19 Netherton syndrome – establishing a genotype to phenotype correlation
C. McDonald, N. Yerlett, J. Mellerio and A. Martinez
- PA20 Developing Diagnostic criteria for PSoriasis in Children (The DIPSOC study): a protocol for a multicentre diagnostic accuracy study designed with the Young Person's Advisory Group for research
E. Burden-Teh, R. Murphy, S. Ratib, T. Nijsten, K. Widdowson and K. Thomas
- PA21 Steroid allergy in children
S. Odedra and D.A. Thompson
- PA22 Angiolymphoid hyperplasia with eosinophilia presenting as a rapidly enlarging, vascular lesion on the cheek of a 13-year-old boy
V. Prince, A. Cummins, C. Mitchell, A. Plant, M. Glover and A. Belgi
- PA23 Bilateral erythematous patches: a diagnostic clue to branchio-oculo-facial syndrome
P. Patel, G. Millington and S. Holden
- PA24 Improving waiting times and compliance for patients on isotretinoin
S. Akhtar, C. Thomas, L. Godsall, A. Mughal and S. Blackford
- PA25 Congenital disorder of glycosylation SRD5A3 associated with psoriasiform rash
M.-L. Lovgren, P. French, V. Murday, P.H. Robinson and P.E. Beattie

- PA26 Abstract withdrawn
- PA27 Herpes Zoster presenting as a painful limp
H. Whitehouse and R. Rose
- PA28 A neonate with an isolated sternal cleft and abdominal raphe
L. Scrivens, J. Halpern and C. Kasparis
- PA29 A new programmatic interface to record sickness data for school children in the U.K.
M. Patel, N. Alwash and J. Felton

The poster viewing session will take place during the lunch break on Thursday 5th July

Notes

Date: Thursday 5th July
Time: 08:30 – 12:15
Room: Fintry
Chair: Dr Victoria Goulden & Dr Sophie Weatherhead
 Dr Bob Sarkany & Dr Hiva Fassihi

08:30 - 08:40	PD02	Isolated actinic lichen planus of the lower lip <u>N. Machnikowski</u>, D. Bilsland, R. Dawe, S. Ibbotson and M. Sivaramakrishnan
08:40 - 08:50	PD03	Localized inflammatory reactions at sites of subcutaneous methotrexate injections during treatment with ultraviolet B <u>S. Muthiah</u>, F. Charlton and P. Farr
08:50 - 09:05	PD04	'Actinic Prurigo': a phrase describing four different diseases in four different continents <u>E. Boontaveeyuwat</u>, J. Mcfadden, H. Fassihi and R. Sarkany
09:05 - 09:15	PD01	Effects of ultraviolet radiation on blood pressure in a large chronic haemodialysis patient cohort <u>R. Weller</u>, Y. Wang, J. He, F. Maddux, L. Usvyat, H. Zheng, M. Feelisch and P. Kotanko
09:15 - 09:30	PD05	Broad spectrum localized abnormal photosensitivity syndrome: a case series review <u>A. Khalid</u>, F. Mahmood, M. Sivaramakrishnan, R. Dawe and S. Ibbotson
09:30 - 09:45	PD06	Narrowband UVB treatment for psoriasis is highly economical and cost-saving with reduced need for topical therapy <u>K. Boswell</u>, H. Cameron, J. West, C. Fleming, S. Ibbotson, R. Dawe and J. Foerster
09:45 - 10:15	PDGL1	Guest Lecture: Home Phototherapy Dr Robert Dawe (Dundee)
10:15 - 10:45	Break	Exhibition Halls
10:45 - 11:15	PDGL2	Guest Lecture: Drug Photosensitivity Prof Sally Ibbotson (Dundee)
11:15 - 11:30	PD07	Do photosensitizing medications increase the risk of developing important erythematous episodes during UVB phototherapy? G. Harrop, R. Dawe and <u>S. Ibbotson</u>
11:30 - 11:45	PD08	A randomized, controlled trial of portable compared with conventional photodynamic therapy for superficial nonmelanoma skin cancer <u>S. Ibbotson</u>, R. Dawe, H. Moseley, I. Samuel and J. Ferguson

Notes

British Hair and Nail Society

- Date:** Thursday 5th July
Time: 10:30 – 12:30
Room: Moorfoot & Kilsyth
Chair: Dr Anita Takwale & Dr Abby Macbeth

Programme

- ## Notes

Posters

- BH07

Comparison study of sertaconazole 2% cream vs. naftifine 1% gel in the treatment of seborrheic dermatitis
M. Goldust, G.R. Rokni and H. Alopour
- BH08

Vitamin D status in patients with frontal fibrosing alopecia
E. Gilhooley, A. Kelly and A. Lally
- BH09

Concurrent alopecia areata and frontal fibrosing alopecia in a male patient
D. Tang, V. Gajawada and D. Jain
- BH10

Localized acquired trichorrhexis nodosa: a case to raise a few eyebrows
R. Jerrom, D. de Berker, J. Hague and M.R. Kaur
- BH11

Contact immunotherapy with diphenylcyclopropenone for alopecia: real-world data from a tertiary referral centre
N. King, J. Bamgboye, S Mirhadi and A. Abdullah
- BH12

Efficacy and cost-effectiveness of diphenylcyclopropenone alone or in combination with dithranol for alopecia areata
D. Tang, S. Alderson, S. Wahie and T. Sripathy
- BH13

Folliculitis decalvans in the era of antibiotic resistance: microbiology and antibiotic sensitivities in a tertiary hair clinic
L. Asfour and M. Harries
- BH14

A curious case of yellow nails
T.S. Chohan, S. Odedra and A. Abdullah
- BH15

Contact allergy to wigs in cases of alopecia areata
J.R. Brockley and D.A. Thompson
- BH16

A middle-aged white female with acquired progressive kinking of hair: a case report and review of the literature
M.-A. Gkini and V. Jolliffe
- BH17

A case of complete loss of all fingernails following application of gel nail polish
N. Alwash and P. Gupta

The poster viewing session will take place during the lunch break on Thursday 5th July



Plenary Session – Tropical Disease

Date: Thursday 5th July
Time: 13:00-15:15
Room: Pentalnd
Chair: Dr Ruth Murphy & Dr Nick Levell

Programme

- 13:00 – 13:20

Invited Lecture
Tropical Dermatology - cases from a clinic near you
Dr Rachael Morris-Jones (London)
- 13:20 – 13:40

Invited Lecture
What's new in global health dermatology?
Dr Claire Fuller (London)
- 13:40 – 14:15

Invited Lecture
Dermatology Training in Ethiopia
Dr Richard Weller (Edinburgh) & Dr Dagnachew Shibeshi (Addis Ababa, Ethiopia)
- 14:15 – 14:30

Presidents Address
Dr Ruth Murphy
- 14:30 – 15:15

Arthur Rook Oration – Introduced by **Dr Ruth Murphy**
Reducing waste in dermatology research
Prof Hywel Williams (Nottingham)



In 2009, Chalmers and Glasziou suggested that up to 85% of medical research is wasteful¹. Much as we might like to think that research waste does not occur in dermatology, the truth is that a lot of our clinical research is done without any form of prioritisation that takes existing research into account. Studies are often poorly designed and many are not reported at all or reported in a biased unusable way. In this talk, I shall suggest some solutions to the pernicious problem of research waste by highlighting some of our work at the Centre of Evidence-Based Dermatology. These solutions include mapping existing evidence, prioritising research questions that are important to patients through priority setting partnerships, promoting prospective registration of researchc protocols to prevent cheating, developing core outcome sets so that studies can be compared and combined, working with methodologists to ensure robust study design, publishing 100% of planned research and making sure that clinically relevant results are disseminated effectively to a community of research users.

Reducing research waste is everyone's business that includes clinicians, nurses, methodologists and patients.

Key reference: 1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009; 374:86-89



Dermoscopy Update Teaching Session

Date: Thursday 5th July
Time: 15:30-17:00
Room: Sidlaw
Chair: Dr Catriona Henderson

Programme

15:30 – 15:52	DTS01	Inflammoscopy Update Dr Anthony Downs (Exeter)
15:52 – 16:14	DTS02	Red and Yellow – what these colours mean to the dermocopist Dr Stephen Hayes (Southampton)
16:14 – 16:36	DTS03	Difficult to diagnose melanoma Dr Catriona Henderson (Southampton)
16:36 – 16:58	DTS03	Update from the 5th World Congress of Dermoscopy 2018 Dr Ben Esdaile (London)

Notes

Cases from the British Society for Medical Dermatology

Date: Thursday 5th July

Time: 15:30-17:00

Room: Fintry

Chair: Assoc Prof Michael Ardern-Jones

Co-chairs: The British Society for Medical Dermatology Committee

Learning Objectives

This CPD session will encompass a variety of complex medical dermatology cases presented in a test-yourself format including an audience response system and panel discussion of each case.

Following this session, the attendee should be able to:

1. Visually identify and diagnose classic and atypical presentations of cutaneous manifestations of systemic disease.
2. Select management options for complex medical dermatologic disease based on the best available evidence from the literature.
3. Discuss the use of advanced systemic therapies for the management of refractory dermatologic conditions.

15.30-15.45	Case 1
15.45-16.00	Case 2
16.00-16.15	Case 3
16.15-16.30	Case 4
16.30-16.45	Case 5
16.45-17.00	Case 6

Health service delivery, management research and GIRFT symposium

Date: Thursday 5th July
Time: 15:30-17:00
Room: Tinto
Chair: Dr Nick Levell & Dr Tanya Bleiker


Programme

15:30 – 15:30	Welcome & Introduction
15:35 – 15:45	GIRFT01 Getting It Right First Time: provision of dermatology services in England J.L.C. Wong and N. Levell
15:45 – 15:55	GIRFT02 Battling the bleep: advocating the relevance of the dermatology on-call C. Ward and P. Laws
15:55 – 16:05	GIRFT03 Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic randomized controlled trial of clinical and cost-effectiveness M. Santer, K. Thomas, M. Ridd, N. Francis, B. Stuart, K. Rumsby, M. Chorooglou, A. Roberts, P. Little and H. Williams
16:05 – 16:15	GIRFT04 Facilitating local treatment with NHS England funded drugs: using Network On-Call Referral Service (NORSe) in dermatology for funding approval via designated specialist centre M.-L. Lovgren, S. Velangi, S.-L. Chua, A. Martin-Clavijo, F. Chaudhri and H. Lewis
16:15 – 16:25	GIRFT05 Optimization of the four-hour clinical session: dermatology SBRI Scotland C. Morton, L. MacFarlane, D. Torley and G. Wylie
16:25 – 16:45	Practising Realistic Medicine Dr Helen MacKie (National Clinical Advisor: Realistic Medicine, CMO’s Office: Scottish Government)
16:45 – 17:00	Panel Discussion

Thanks to Junie Wong whose original idea stimulated discussions which have lead to the development of this new symposium



Skin clearance should stand the test of time



For superior skin clearance vs adalimumab
TREMFYA® achieved PASI 90 in **73.3%** of patients at 16 weeks, compared with **49.7%** on adalimumab ($P<0.001$)¹

For long-lasting skin clearance
TREMFYA® maintained PASI 90 up to 100 weeks in **83.8%** of patients²

For skin clearance with a generally well-tolerated safety profile*
TREMFYA® has no specific class effect warnings for candidiasis, Crohn’s disease, demyelinating diseases or congestive heart failure^{3†}

Stand for lasting skin clearance with TREMFYA™²

IL = Interleukin; PASI = Psoriasis Area and Severity Index.
* The most common adverse drug reaction was upper respiratory infection.
† Special warning and precautions for Tremfya: infections, tuberculosis, serious hypersensitivity reaction and immunisations (please see prescribing information below for further details)

Tremfya ▼ 100 mg solution for injection
ACTIVE INGREDIENT(S): guselkumab
Please refer to Summary of Product Characteristics (SmPC) before prescribing.
INDICATION(S): Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. **DOSAGE & ADMINISTRATION:** For use under guidance/supervision of physician experienced in diagnosis and treatment of plaque psoriasis. Subcutaneous injection. Avoid areas showing psoriasis. **Adults:** 100 mg at weeks 0 and 4, followed by maintenance dose every 8 weeks. Consider discontinuation if no response after 16 weeks of treatment. **Children:** No data available in children/adolescents <18 years. **Elderly:** No dose adjustment required, limited information in subjects aged ≥ 65 years. **Renal & Hepatic impairment:** Not studied. **CONTRAINDICATIONS:** Serious hypersensitivity to active substance or excipients; clinically important, active infection. **SPECIAL WARNINGS & PRECAUTIONS:** **Infections:** Potential to increase risk. If signs/symptoms of clinically important chronic/acute infection occur, monitor closely and discontinue Tremfya until resolved. **Tuberculosis:** Evaluate patients for TB pre-treatment; monitor for signs/symptoms of active TB during and after treatment. Consider anti-TB therapy prior to Tremfya if past history of latent/active TB and adequate treatment course not confirmed. **Serious hypersensitivity reaction:** If occurs, discontinue Tremfya immediately and initiate appropriate

therapy. **Immunisations:** Consider completing all appropriate immunisations prior to Tremfya. Do not use live vaccines concurrently with Tremfya; no data available; before live vaccination, withhold Tremfya for at least 12 weeks and resume at least 2 weeks after vaccination. **SIDE EFFECTS: Very common:** Upper respiratory infection. **Common:** Gastroenteritis, herpes simplex infections, tinea infections, headache, diarrhoea, urticaria, arthralgia, injection site erythema. **Refer to SmPC for other side effects.** **PREGNANCY:** Avoid use of Tremfya; no data. Women of childbearing potential should use effective contraception during and for at least 12 weeks after treatment. **LACTATION:** Discontinue breast-feeding during treatment and up to 12 weeks after the last dose, or discontinue Tremfya. **INTERACTIONS:** No dose adjustment when co-administering with CYP450 substrates. Concomitant immunosuppressive therapy or phototherapy not evaluated. **Refer to SmPC for full details of interactions.** **LEGAL CATEGORY:** POM
PRESENTATIONS, PACK SIZES, MARKETING AUTHORISATION NUMBER(S) & BASIC NHS COSTS:

PRESENTATIONS	PACK SIZES	MARKETING AUTHORISATION NUMBER(S)	BASIC NHS COSTS
Pre-filled syringe	X 1	EU/1/17/1234/001	£2250

MARKETING AUTHORISATION HOLDER: Janssen-Cilag International NV,

Turnhoutseweg 30, B-2340 Beerse, Belgium. **FURTHER INFORMATION IS AVAILABLE FROM:** Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG UK. Prescribing information last revised: November 2017.

Adverse events should be reported. ▼ This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at dsafety@its.jnj.com.

© Janssen-Cilag Limited 2017

References:
1. Blauvelt A *et al.* *J Am Acad Dermatol* 2017; 76(3): 405–417.
2. Griffiths CEM *et al.* Oral presentation at: European Academy of Dermatology and Venereology (EADV) 26th Annual Congress; September 13–17, 2017; Geneva, Switzerland.
3. Janssen-Cilag Ltd. TREMFYA® Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc> (last accessed: May 2018).



Hot Topics

They will be semi-informal set-up taking place in two designated areas within the Exhibition Halls during the breaks. These are highlighted as **HT1** (Cromdale Hall) and **HT2** (Lennox Hall) on the exhibition plan.

Tuesday 3rd July

Time	Hot Topic Zone	Title	Speaker(s)
10:30 – 11:00	HT1 (Cromdale Hall)	Mobile Devices	Dr David de Berker
10:30 – 11:00	HT2 (Lennox Hall)	Compliance with the Cosmetic Registry	Dr Emma Craythorne
14:30 - 15:00	HT1 (Cromdale Hall)	What's new in oestrogens for vulvovaginal disease	Dr Susan Cooper Dr Stephanie Arnold
14:30 - 15:00	HT2 (Lennox Hall)	TEN in Children	Dr Tess McPherson

Wednesday 4th July

Time	Hot Topic Zone	Title	Speaker(s)
10:30 – 11:00	HT1 (Cromdale Hall)	Practical Job Planning	Dr Kid Wan Shum
10:30 – 11:00	HT2 (Lennox Hall)	Top Tips in Getting Published	Prof Alex Anstey Dr George Millington Prof Bruce Thiers
15:30 – 16:00	HT1 (Cromdale Hall)	What's new in the guidelines for the management of pemphigus vulgaris	Dr Jane Setterfield
15:30 – 16:00	HT2 (Lennox Hall)	What's new in psychodermatology	Dr Alia Ahmed

Thursday 5th July

Time	Hot Topic Zone	Title	Speaker(s)
10:15 – 10:45	HT1 (Cromdale Hall)	What's new in UVA1 therapy	Dr Angela Tewari Dr Ljubomir Novakovic
10:15 – 10:45	HT2 (Lennox Hall)	Managing itch, what new in the guidelines	Dr George Millington

Pharma Workshop

They will be semi-informal set-ups taking place on Tuesday lunchtime in **HT2** (Lennox Hall) on the exhibition plan.

Tuesday 3rd July

Time	Hot Topic Zone	Company Title	Speaker(s)
12:15 – 12:30	HT2 (Lennox Hall)	Janssen The pathophysiology of PsA: identifying key cytokines	Prof Dennis McGonagle
12:30 – 12:45	HT2 (Lennox Hall)	Leo Pharma The importance of early treatment with fixed dose combination therapies in adult plaque psoriasis	Dr Faisal Ali
12:45 - 13:00	HT2 (Lennox Hall)	Lilly Arthritis Examination for Dermatologists	Dr Helen Harris

Lunchtime Journal Club

They will be semi-informal set-up taking place in designated areas within the Exhibition Halls during breaks. These are highlighted as **HT1** or **HT2** on the exhibition plan. This new initiative will feature presentations of recent papers which will have a significant impact on the management of skin disease.

Tuesday 3rd July

Time	Hot Topic Zone	Speaker(s)
12:15 – 12:45	HT1 (Cromdale Hall)	Dr Jonathan Batchelor & Dr Rosalind Simpson

Thursday 5th July

Time	Hot Topic Zone	Speaker(s)
12:15 - 12:45	HT2 (Lennox Hall)	Dr Zenas Yiu & Dr Zarif Jabbar-Lopez



Poster Walks

We are delighted to introduce to the Edinburgh Annual Meeting our new interactive poster walks. These expertly lead educational strolls through selected posters will be based broadly on several different themes and feature discussions on the key findings of the papers presented. Please ensure you sign up at the registration desk for the limited number of places.

Once signed up you will receive a golden ticket which should be presented at the poster desk prior to the start of the selected time. At this stage you will be provided with the headphones to listen to the experts as they take you on the guided walks. Please do feel free to ask questions and interact, in this fun and educational new initiative to the meeting.

Here are the walk leaders and themes, the selected posters will be listed in the final programme.

Tuesday 3rd July

Time	Topic	Poster Walk Leaders	Posters Selected
10:30 – 11:00	Photodermatology	Dr Bob Sarkany, Dr Hiva Fassihi	H23, P067, PA12, PA13, PD14
10:30 – 11:00	Surgery	Dr Irshad Zhaki, Dr Wal Hussain	DS27, DS33, DS34, DS36, DS38, DS49, DS54
14:30 - 15:00	Genetics	Dr Jemima Mellerio, Dr George Millington	BG08, BG09, PA25, BG11, BG12, BG13, BG15
14:30 - 15:00	Dermatopathology	Dr Alistair Robson, Dr Manuraj Singh	P001, P005, P006, P013, DP12, DP21, DS29, DS38, DS54, BI17

Wednesday 4th July

Time	Topic	Poster Walk Leaders	Posters Selected
10:30 - 11:00	Hair and Nails	Dr Vicky Jolliffe, Dr David de Berker	PA14, BH14, DS40, P054, P066, BH17
10:30 - 11:00	Allergy	Dr Graham Johnston, Dr Donna Thompson	CD16, CD20, CD26, CD22, CD14
15:30 - 16:00	Basic Science	Dr Richard Weller, Dr Carsten Flohr	P038, P049, P053, P069, DS41
15:30 - 16:00	Medical Dermatology	Prof David Burden, Dr Andrew Carmichael	P010, P028, P086, P008, P016, P076

Thursday 5th July

Time	Topic	Poster Walk Leaders	Posters Selected
10:15 - 10:45	Paediatrics	Dr Nigel Burrows, Dr Carolyn Charman	PA11, PA12, PA21, P039, P013, PA19, DC01, PA25, P048
10:15 - 10:45	Psychodermatology	Dr Janet Angus, Dr Andy Affleck	P019, P029, PS16, PS17, PS19



Posters

The posters are situated on the mezzanine level. The poster viewing session will take place during the lunch breaks on Tuesday (even numbered posters) and Thursday (odd numbered posters). All presenting authors have been asked to stand by their posters at this time. There will also be an e-poster display in the organiser's room also located on this level.

Clinicopathological Cases

P01	A rare cause of blistering: aggressive bullous cutaneous T-cell lymphoma <u>N. Watson</u>, S. Fatah, C. Bacon, J. Frew and S. Weatherhead
P02	A case of amiodarone-induced iododerma <u>A. Tidman</u>, J. Burton, C. Clark and R. Gardner
P03	Erythroderma following ustekinumab therapy for psoriasis <u>E.N. Dhonncha</u>, Q. Razali, L. Roche and T. Markham
P04	An encounter with blisters and scales <u>Y.L. Teoh</u>, <u>H.L. Kwong</u> and <u>C.C. Ang</u>
P05	A case of hypertrophic lichen planus mimicking multiple squamous cell carcinomas <u>B. Ho</u> and <u>V. Samarasinghe</u>
P06	An uncommon presentation of hand foot and mouth disease in an adult male <u>E. Gilhooley</u>, <u>P. Hartel</u> and <u>D. Mc Kenna</u>
P07	Lichen aureus masquerading as acral melanoma <u>G.M. Callaghan</u>, <u>C. O’Keane</u> and <u>F.J. Moloney</u>
P08	Novel management of the under diagnosed and difficult to treat arteriosclerotic ulcer of Martorell <u>L. Hanna-Bashara</u>, <u>A. Bakshi</u>, <u>P. Brackley</u> and <u>E. West</u>
P09	A case of acute generalized exanthematous pustulosis secondary to exemestane <u>A. Tidman</u>, <u>I. Ngu</u>, <u>R. Blair</u> and <u>C. Jury</u>
P10	Amelanotic lentigo maligna masquerading as vitiligo <u>B. Salence</u>, <u>S. Cliff</u>, <u>M. Cook</u> and <u>B. Powell</u>
P11	Abstract withdrawn
P12	Fingolimod-induced primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma <u>A. Connolly</u>, <u>V. Grandi</u>, <u>C. Stephanato</u>, <u>R. Palmer</u> and <u>S. Whittaker</u>
P13	A rare case of spitzoid melanoma in a paediatric patient: the challenges <u>B. Ganatra</u>, <u>R. Carr</u>, <u>A. de la Fouchardière</u> and <u>E. Howard</u>

General Dermatology

P14	Patient-reported insights from the APPRECIATE study: real-world experience of psoriasis patients treated with apremilast in the U.K. and Ireland <u>K. Shams</u>, <u>P. Laws</u>, <u>K.S. Chen</u>, <u>M. Cordey</u>, <u>C. Elise Kleyn</u> and <u>C.E.M. Griffiths</u>
P15	Association between Absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) in bionaïve patients after 36 months of treatment with ustekinumab: data from the British Association of Dermatologists Biologic Interventions Register (BADBIR) registry <u>K. Hampton</u>, <u>L. Deavy</u>, <u>J. Chin</u>, <u>E. Lee</u>, <u>X. Wu</u> and <u>J. Diels</u>



- P16 Orofacial granulomatosis: a review of 25 cases seen by an Oral Medicine/Dermatology network
U. Popli, C. Graham, J.A. Callander, B.P. Rajlawat, D. Holt and P.D. Yesudian
- P17 Validation of an electronic application of the Psoriasis Area Severity Index (PASI)
F. Ali, S. Salek, V. Piguet and A. Finlay
- P18 Case series reviewing presentation and treatment of patients with refractory cutaneous Crohn's and hidradenitis suppurativa in a tertiary Dermatology Stoma Clinic
L. Asfour and C. Lyons
- P19 Delusional infestation: perspectives from Scottish dermatologists and a 10-year case series from a single centre
Y.L. Wong, A. Affleck and A.M. Stewart
- P20 Social media and psoriasis treatments: what are patients with psoriasis saying on Twitter?
S. Menzies, S. Daly and D. McKenna
- P21 Cardiovascular risk profile of psoriasis patients in a nonselected psoriasis service
E. Hayashi, L.L. Shabeer and P.M. Laws
- P22 The role of U.K. dermatology patient support groups
E. McNulty-Brown, W.A. Woo and S. George
- P23 Abstract withdrawn
- P24 Increase in concentration of allergen decreases occlusion and patch test reaction time: a time-dose relationship for patch test reactivity!
K. Verma, S. Hima Bindu, G. Sethuraman and M. Kalaivani
- P25 Blaschkoid pigmentation, keloids and disabling digital fibromas in Borjeson-Forssman-Lehmann syndrome
S.H. Foo, C. Moss, R. Goodwin, S.F. Corrin and A.E. Fry
- P26 Paediatric vulval lichen sclerosus: a case series
D. Ismail and C.M. Owen
- P27 Clinical signs of epithelial surface disruption impact pain and sexual health in patients with moderate-to-severe genital psoriasis
J. Lambert, P.-D. Ghislain, J. Merola, A. Potts-Bleakman, A.J.M. Brnabic, R. Burge and E. Riedl
- P28 Oral rifampicin and clindamycin is an effective treatment in severe recalcitrant acne: a case series
N. Lee, H. Whitehouse, E. Horton, A. Eady and A. Layton
- P29 The psychological burden of skin disease in adult dermatology outpatients
K. Lockwood, A. Al Haddabi and S. Weatherhead
- P30 Detecting psoriatic arthritis in a specialist dermatology clinic
D. Maslin, S. Sharma, D. Jadon, P. Norris and S.H. Hussain
- P31 Atypical variants of erythema nodosum leprosum: a case series
G. Sawatkar, R.P. Singh, P. Debnath and V. Wankhade
- P32 Burden of skin disease in cystic fibrosis: experience of a tertiary referral centre
C. Angwin, N. Papalexopoulou and S. Singh
- P33 A unique presentation of 'petrified ears' with pain due to fracture
L. Thomas, K. Naidoo and A. Carmichael
- P34 Melanotan II perceptions and experience: a qualitative study of online discussion forums
E. Gilhooly, S. Daly and D. Mc Kenna
- P35 An observational study to determine carotid artery intima media thickness in patients with psoriasis with and without metabolic syndrome
A. Kaushik, S. Handa, T. Narang and C. Ahuja

- P36 Assessment of quality of life with treatment in morphea patients
A. Uthayakumar, A. Ahmed and C. Orteu
- P37 Clinicoepidemiologic and dermoscopic features of alopecia areata in children: a report from tertiary care institute in north India
M. Daroach, R. Mahajan, D. De and S. Handa
- P38 Targeting mitochondrial iron in Friedreich's ataxia skin cells protects them from ultraviolet A-induced cell death
O. Reelfs, V. Abbate, R. Hider and C. Pourzand
- P39 Zinc deficiency and protein-energy malnutrition in a child with atopic eczema
L. Thomas, K. Naidoo and S. Darné
- P40 Lipoprotein analysis in hidradenitis suppurativa
S. Kirthi, C. Gallagher, J. Gibney, L.-A. Behan, G. Boran, P. Reilly, M. Connolly and A.-M. Tobin
- P41 Validation and reliability assessment of acquired dermal macular hyperpigmentation area and severity index (DPASI)
G. Dabas, K. Vinay, S. Kumaran and D. Parsad
- P42 Omphaloliths: a systematic review and meta-analysis
L.F. Soriano, P. Pathmarajah, S. Rajpopat, D. Markiewicz and A. Sahota

GIRFT

- P43 A qualitative analysis of patient experience of wait times in routine dermatology referral
L. Ferguson, K. Jordan, I. Plumptre, J. Shelley and L. Claire Fuller
- P44 Absence of clinically relevant information in referrals to secondary care for patients with acne vulgaris
D. O'Driscoll, E. Conroy-Smith, P. Jeevaratnam, I. Pearson and E. Healy
- P45 Neglect of skin examination by generalists. . .closing the loop
D. Chandler
- P46 Dermatopathology request forms: a study of data completeness and accuracy between specialties
Z. Sawafta, C. Oakley, D. Cundell and J.M.R. Goulding
- P47 Development of a 'Spot Clinic': an innovative approach to pre-2-Week Wait (2WW) skin lesion triage
J. Schofield, V. Blankley, K. Hussain and K. Scharrer
- P48 Establishing and developing a novel teenage and young adult dermatology clinic: a model for developmentally appropriate skin health care
R.M. Fisher and T. McPherson

Skin Cancer

- P49 Lack of positive correlation of blood and skin involvement in patients with mycosis fungoides and Sézary syndrome: a multicentre European study
A. Wernham, R. Stranzenbach, R. Stadler, P. Ortiz-Romero, E. Guenova, P. Quaglino, E. Hodak, E. Papadavid, U. Wehkamp, F. Evison, M. Bagot and J. Scarisbrick
- P50 Don't be a Lobster: a novel way of promoting sun protection in British beaches
A. Mughal, J. Peconi, S. Wright, G. Crawford, A. Carter and R. Frame
- P51 A national centre's experience of Glasshouse Photodynamic Therapy
G. Callaghan, F. Moloney, E. Shudell, N. Ralph, A. Murad, S. Menzies and P. Lenane
- P52 Application of SPF moisturizers is inferior to sunscreens in terms of percentage coverage of facial and eyelid area
E. Lourenco, H. Pratt, K. Hamill, G. Czanner, Y. Zheng and A. McCormick

- P53 No relationship found between serum vitamin D levels and prognostic indices of malignant melanoma, in contrast to previous studies
B. Olabi, H. Smith, A. Panthagani, S. Ratib, M. Lam and S. Varma
- P54 The advantage of teledermoscopy in the early detection of amelanotic/hypomelanotic melanoma
A. Atwan and C. Mills
- P55 Spotlight on lentigo maligna
Z.C. Venables, E. Craythorne, I.M. Leigh and R. Patalay
- P56 The burden of cutaneous disease in solid organ transplant recipients with skin of colour
J. Kentley, L. Mitchell, C. Harwood, J. McGregor and C. Proby
- P57 High-risk SCC: Sorting the wolves from the sheep
C. Kiely, R. Mallipeddi and E. Craythorne
- P58 Dermoscopic features of amelanotic/hypomelanotic melanoma: a review of 17 cases
A. Atwan and C. Mills
- P59 'Doughnut' Mohs micrographic surgery in the treatment of extramammary Paget's disease at a specialist skin cancer referral centre
C. Peng, A. Martin-Clavijo and S. Velangi
- P60 Use of reflectance confocal microscopy in a U.K. secondary care environment shows a high correlation between histological and confocal diagnosis of both melanoma and basal cell carcinoma (BCC)
H. Stevens, J. El Jabbour and R. Stevens
- P61 Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients and those with more extensive skin involvement
K. Molloy, C. Peng, R. Cowan, E. Parry, A. Busschots, E. Hauben, M. Bayne, A. Bates, K. Benstead, J. Yoo, C. Jonak and J. Scarisbrick
- P62 Assessing the use of a *melanoma checklist*: does it improve adherence to the NICE melanoma guidelines?
S. Wright, S. Basrai, C. Roberts and R. Abbott
- P63 An ageing population and increase in Merkel Cell Carcinoma in a West-Yorkshire skin cancer service: a 7-year review
A. Whittam, A. Wright and S. Al-Ghazal
- P64 Wood's lamp: Illuminating our surgical margins!
A. Atwan and C. Mills
- P65 A study of primary management in cases of recurrent or metastatic cutaneous squamous cell carcinoma of the ear
K.H. Kuet, N. Tiffin and A. McDonagh
- P66 The fate of the two-week-wait: a retrospective overview of melanoma skin cancer referrals from primary care to secondary care
K. Sinha, N. Attard and R. Patalay
- P67 Improving sun protection in adolescents and young adults: a systematic review of intervention effectiveness
N. Gopee, C. Hibberd and P. Abhyankar
- P68 A survey of sun-protection practices among triathletes
W.A. Woo, R. Wilmot, N. Alwash, J. Coe, L. Mathew, E. McNulty-Brown, M. Patel, P. Farrant and S. George
- P69 Enhancement in imiquimod permeation through microneedle skin pretreatment
A.H. Sabri, E. Cocks, V. Shpadaruk, J. Mckenna, D. Scurr and M. Marlow

Education, Training, Services, Audit

- P70 Audit of inpatient referrals using 'Referring Wisely' Guidance in a Busy District General Hospital Dermatology Department
J. Miller and C. Soon
- P71 An audit comparing pain scores during conventional and white light topical 5 methyl aminolaevulinic acid photodynamic therapy for superficial basal cell carcinoma and squamous cell carcinoma *in situ*
R. Hellen, E.N. Dhonncha, A. Havelin, L. Fleming, A. Kavanagh, B. Moriarty and P. Collins
- P72 Increase in number of patients attending general practitioners in England with acne: sentinel network database study 2006–2016
J. Schofield and S. de Lusignan
- P73 Junior Doctors confidence in managing dermatological conditions
A. Adel and A. Protonotarios
- P74 A retrospective analysis of the use of iontophoresis for hyperhidrosis at a District General Hospital
C. Gollins, A. Carpenter, C. Steen, H. Bulinski and R. Mahendran
- P75 The importance of procedural consent in dermatology: patients' perspective
A. Randhawa and G. Wylie
- P76 The role of visual literacy training in enhancing clinical skills in higher specialty trainees
C.H. Tiu, M. Jakab, H. Tomlin, C. Griffiths and H. Young
- P77 Willan library cataloguing and digitizing
L. Exton, A. Shipman, K. Birkwood, J. Beckwith and N. Levell
- P78 Vorticism: a manifesto for dermatology training?
H. Young, C.H. Tiu, M. Jakab, H. Tomlin and C. Griffiths

Therapy

- P79 Dupilumab leads to no or low disease activity in most moderate-to-severe atopic dermatitis patients: signs, symptoms and quality of life
A. Blauvelt, Z. Chen, T. Hultsch, L. Eckert, A. Gadkari, B. Shumel and M. Ardeleanu
- P80 Real-world experience of Omalizumab in a U.K. Tertiary Urticaria Clinic: a series of 113 cases
A. Khoo and A. Marsland
- P81 Are we spot on? A trainee-led regional survey of prescribing practice of oral isotretinoin for acne
S. Mirhadi, J. Carr, G. Petrof, S. Tso, A. Cuell, S.Z. Jaulim, G. Fremlin and A. Wernham
- P82 The importance of pre-dupilumab ophthalmology assessment: real-life experience demonstrating its value
K. Molloy, R. Barry, S. Rauz and S. Velangi
- P83 A single centre, 5-year retrospective cohort study of methotrexate-treated patients undergoing serial serum aminoterminal peptide of collagen III testing finds no cases of liver fibrosis
A. Banner, G. Bayly, F. Gordon and C. Mahon
- P84 Management of psoriasis during pregnancy: two cases of infliximab use and a review of safety evidence of systemic medications
J.M. Gao, L. Ferguson and N. Roberts
- P85 UK and Ireland real-world experience with apremilast in psoriasis patients: analysis of 126 patients from the APPRECIATE study
C. Elise Kleyn, P. Laws, K.S. Chen, J. Eccles, M. Cordey and C.E.M. Griffiths

- | | |
|------|--|
| P86 | Folate deficiency in adults with severe atopic eczema: should we screen and treat before methotrexate? A single centre, retrospective case review
<u>S. Khan</u>, A. Sobczyńska-Malefora, S. Langan, C. Smith and E. Higgins |
| P87 | Dupilumab improves atopic dermatitis equally well in all anatomical regions: data from the LIBERTY phase III clinical trials
<u>A. Blauvelt</u>, E. Simpson, T. Bieber, M. Kawashima, D. Rosmarin, B. Shumel, Z. Chen, T. Hultsch and M. Ardeleanu |
| P88 | Correlation of Dermatology Life Quality Index and gravimetric analysis for patients with hyperhidrosis treated with botulinum toxin
<u>S. Akhtar</u>, C. Thomas and A. Mughal |
| P89 | A practical approach to methotrexate monitoring, incorporating the up-to-date BAD guidance and use of FibroScan
<u>S. Hadjieconomou</u>, A. Yeoman and N. Stone |
| P90 | Use of secukinumab in a difficult to treat population of anti-TNFα failure psoriasis patients from the U.K. and Republic of Ireland: results of the SIGNATURE study up to 72 weeks
<u>R. Warren</u>, J. Barker, D. Burden, A. Finlay, C. Hatchard, Y. Armendariz, R. Williams and C. Griffiths |
| P91 | Mucocutaneous adverse effects affecting the genital and perianal skin on isotretinoin therapy
<u>L. Cunningham</u>, S. Menzies, A. Murad, E. Shudell, F. Moloney and N. Ralph |
| P92 | A split-face randomized controlled trial comparing 1064 nm Q-switched Nd-YAG laser and modified Kligman's formulation in darker skinned patients with melasma
<u>T. Dev</u>, V. Sreenivas, V. Sharma, K. Sahni, N. Bhari and G. Sethuraman |
| P93 | Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre
<u>L. Griffin</u>, B. Ramsay, C. Hackett, K. Ahmad, J. Boggs and M. Lynch |
| P94 | Topical tazarotene as a useful alternative to microneedling in atrophic postacne scarring: a randomized clinical trial
<u>T.P. Afra</u>, T. Narang, S. Dogra and T. Muhammed Razmi |
| P95 | Successful treatment of extensive ulcerating necrobiosis of the legs with timolol 0.5% eye drops
<u>A. Yaakub</u> and S.N. Shah |
| P96 | Curse or cure: paradoxical side-effects of biological agents
<u>E. Horton</u>, W. Ghumra, I. El-Mansori, A. Layton, A. Eady and N. Lee |
| P97 | IgG4-related skin disease responsive to thalidomide
<u>P.D. Yesudian</u>, S. Murugusundaram, K. Subramanian and P. Yesudian |
| P98 | Circumcision is not always curative in male genital lichen sclerosus
<u>M. Shah</u>, R. Watchorn and C. Bunker |
| P99 | Botox® for craniofacial hyperhidrosis: a patient satisfaction survey
<u>N. Elshimy</u> and C. Love |
| P100 | Severe refractory hidradenitis suppurativa: treatment with ixekizumab, two case reports
<u>C. Cotter</u>, A.M. Tobin, R. O'Connor, C. Gallagher and M. Connolly |
| P101 | Low prevalence of liver fibrosis in patients on methotrexate for psoriasis: is the liver health of these patients improving?
<u>P. Babakinejad</u>, A. Al Haddabi, S. McPherson and P.J. Hampton |
| P102 | Paradoxical scalp psoriasis during anti-TNF-α treatment of Crohn's Disease
<u>B. Murphy</u>, C. McCourt and D. O'Kane |
| P103 | Use of anakinra in treatment-resistant pyoderma gangrenosum
<u>A. Ng</u>, M. Aamer, K.L. Warburton, R. Montgomery and P. Laws |

- P104 Unavailability of common dermatology pharmaceuticals
S. McCusker and G. Wylie
- P105 Self-reported cutaneous side-effects of anti-TNF therapy in inflammatory bowel disease patients
A. Ridge, C. Gallagher, C. Judge, J. Campion, A.M. Tobin, D. Mc Namara and D. Kevans
- P106 A paediatric case of lead poisoning from Ayurvedic medicine for the treatment of nail psoriasis
M. Rajpopat, J. Robinson, Y. Chow, P. Dargan and E. O'Toole
- P107 Factors influencing immediate and delayed pain response to cryotherapy of actinic keratoses
C. Mac Eochagain, J. Mac Mahon, C. Gillespie, H. Kudryashova, L. Killion, P. Lenane, N. Ralph and F. Moloney

Dowling Club Prize Winning Poster

- DC01 Fetal, maternal and perinatal risk factors for the development of infantile haemangiomas in South Asian population
H. Sudusinghe, P. Rathnayake, K. Nanayakkara, S. Pirabakaran, T. Weerasinghe, T. Lukman, T. Loganathan, D. Katugaha, J. Seneviratne and S. Samaraweera

Notes

Exhibition Plan BAD 2018



98th Annual Meeting of the British Association of Dermatologists. EICC Edinburgh, July 2018

Exhibitor Directory

AbbVie Ltd	H10 + J35
Abbvie House, Vanwall Business Park, Maidenhead, Berkshire, SL6 4UB	
TEL: 01628 561090 WEBSITE: www.abbvie.co.uk EMAIL: kerrie.annan@abbvie.com CONTACT NAME: Kerrie Annan	
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.	
Almirall Ltd	H30
Harman House, 1 George Street, Uxbridge, Middlesex, UB8 1QQ	
TEL: +44 (0) 207 160 2500 EMAIL: info.uk@almirall.com CONTACT NAME: Jeff Hart	
Almirall is an international pharmaceutical company with the primary purpose to provide valuable medicines to you and future generations. With headquarters in Barcelona, Spain, Almirall have a strong international interest in Dermatology. Almirall research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people's health and wellbeing.	
Altruist Dermatology Sunscreen	G1
Arnhemseweg 87 3832 GK Leusden The Netherlands	
TEL: +31 33 461 4844 WEBSITE: www.altruistsun.com EMAIL: sunscreen@altruistsun.com CONTACT NAMES: David Westerbeek van Eerten	
Altruist Dermatologist Sunscreen has been developed by Dr Andrew Birnie, a consultant dermatologist and skin cancer surgeon, in partnership with top European scientists; the finest quality UV protection, for the lowest possible price. With reduced profit margins and eliminating unnecessary marketing costs, everyone can afford to be safer – and apply more sunscreen.	
Amgen	G2a
Amgen Limited, 240 Cambridge Science Park, Milton Road, Cambridge, CB4 0WD	
TEL: +44 (0)1223 420305 WEBSITE: www.amgen.co.uk	
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.	
BASCO UK LTD	G2
71-75 Shelton Street Covent Garden London WC2H 9JQ	
TEL: 07853333009 WEBSITE: www.bascoonline.com EMAIL: sales@bascoglobal.com CONTACT NAME: Lyndon Royle	
BASCO UK manufactures equipment for Dermatology, Cosmetology & Hair Transplantation. Our Suite of products includes Liquid Nitrogen Cryo, Dermajet, Radio Frequency Cautery, FUE Extractor, FUE Punches, Optivisors, Woodslamp, Fine Instruments for Dermatology & Hair Transplantation. To get more detailed Information Kindly logon to our Website WWW.bascoonline.com or mail us at sales@bascoglobal.com	



BADBIR	D2
British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) The University of Manchester, Rutherford House (Unit 1 FF), Manchester Science Park, 40 Pencroft Way, Manchester, M15 6SZ	
TEL: 0161 306 1896 WEBSITE: www.badbir.org EMAIL: badbir@manchester.ac.uk CONTACT NAME: Kathleen McElhone, BADBIR Head of Study Operations	
BADBIR is an observational study seeking to assess the long-term safety of new therapies used in the treatment of moderate-to-severe psoriasis in the U.K. and Ireland. Patients starting a biologic, biosimilar or new small molecule immunomodulator are recruited and followed over time. The primary aim of the register is to monitor the safety of these new therapies. A control cohort of psoriasis patients treated only with conventional systemics is also recruited. By comparing the experiences of the patients for the duration of the study, BADBIR will help answer important questions on the long-term use of these new therapies.	
Beiersdorf UK Ltd	D30
2010 Solihull Parkway, Birmingham Business Park, Birmingham, B37 7YS	
TEL: +44 (0)121 329 8800 WEBSITE: www.eucerin.co.uk EMAIL: Eucerin.UK@Beiersdorf.com CONTACT NAMES: Dylan Griffiths / Ben Pattison	
At Eucerin we dedicate all our passion and expertise to demanding and sensitive skin, developing clinically proven solutions to protect, repair and sustain the skin. For over 100 years we have pioneered medical skin science and innovation. Today, Eucerin is trusted and recommended by dermatologists and pharmacists world-wide.	
Biofrontera Pharma GmbH	C1
Hemmelrather Weg 201, 51377, Leverkusen, Germany	
TEL: 07500 085185 WEBSITE: www.biofrontera.com EMAIL: Enquiriesuk@biofrontera.com CONTACT NAME: Sandy Richardson	
Biofrontera is a biopharmaceutical company specialized in the field of dermatology. Our focus lies in the management of NMSC through conventional and daylight-mediated photodynamic therapy. Areas in which we have developed considerable scientific and clinical expertise over many years. Founded in 1997, Biofrontera currently employs around 130 staff worldwide.	
Bio-Oil	C2
Godrej UK, Falcon House, 115-123 Staines Road, Hounslow, TW3 3LL	
TEL: 020853 81250 WEBSITE: www.bio-oilprofessional.co.uk EMAIL: natalias@godrejcp.com CONTACT NAME: Natalia Shelton	
Bio-Oil is an award-winning, specialist skincare treatment that has been clinically proven to improve the appearance of scarring, stretch marks and uneven skin tone. It contains vitamins A, E and natural plant oils, plus PurCellin Oil (TM) that lowers viscosity making it a dry oil. For more information visit www.bio-oilprofessional.co.uk	
British Association of Dermatologists	
Willan House, 4 Fitzroy Square, London, W1T 5HQ	
TEL: 0207 391 0266 WEBSITE: www.bad.org.uk EMAIL: admin@bad.org.uk	
Please visit our exhibition stand in the atrium of the EICC. This is a one stop shop showcasing all aspects of the British Association of Dermatologists. We hope the stand will demonstrate the breadth of activities carried out by the BAD and be a resource for both members and non-members.	



A20

TEL: 0207 391 6341
WEBSITE: www.britishskinfoundation.org.uk
EMAIL: admin@britishskinfoundation.org.uk

E3

TEL: 01256 841045
WEBSITE: www.brymilluk.com
EMAIL: swilliams@brymill.com
CONTACT NAME: Steve Williams

J30

TEL: 0208 831 8300
WEBSITE: www.celgene.co.uk
EMAIL: swoods@celgene.com
CONTACT NAME: Seb Woods

D1

TEL: 020 7388 6515
WEBSITE: www.ilds.org
EMAIL: admin@ilds.org

D10

TEL: +44 (0)1565 654920
WEBSITE: <http://www.crawfordhealthcare.com/>
EMAIL: info@crawfordpharma.com
CONTACT NAME: Shaunagh Igooe



F12

TEL: 0191 375 9052
WEBSITE: www.dermauk.co.uk
EMAIL: declan.mulholland@dermauk.co.uk
CONTACT NAME: Declan Mulholland

D20

TEL: 01462 458866
WEBSITE: www.dermal.co.uk
EMAIL: lauren.ardolino@dermal.co.uk
CONTACT NAME: Lauren Ardolino

G4

TEL: 01908 376376
WEBSITE: www.diagenics.co.uk
EMAIL: info@diagenics.co.uk
CONTACT NAME: Nicholas Lynch

K15

TEL: 01256 315000
WEBSITE: www.lilly.co.uk

E10

TEL: 01386 832 311
WEBSITE: www.enviroderm.co.uk
EMAIL: info@enviroderm.co.uk
CONTACT NAME: Hilary Packham



Frezyderm

C10

Link House, 140 Broadway Road, Surrey, London, KT6 7HT

TEL: 020 83396131
WEBSITE: www.frezyderm.co.uk
EMAIL: dpapangelis@frezyderm.co.uk
CONTACT NAME: Danae Papangelis

FREZYDERM is a global manufacturer of high-quality dermocosmetics and CE products, which conform to the strictest EU standards, using only raw materials of pharmaceutical grade. Our extensive portfolio comprises of specialised products for both the cosmetic needs of the skin as well as specific dermatological conditions, such as rosacea, psoriasis and eczema.

Galderma (UK) Ltd

B30

69-71 Clarendon Road, Watford, WD17 1DS

TEL: 01923 208950
WEBSITE: www.galderma.co.uk
EMAIL: david.mccormick@galderma.com patricia.ramos@galderma.com
CONTACT NAMES: David McCormick, Patricia Ramos

Created in 1981, Galderma is now present in over 100 countries with an extensive product portfolio of medical solutions to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails. For more information, please visit www.galderma.com

HEINE Optotechnik

E15

Kientalstraße 7, 82211 Herrsching, Germany

TEL: 0049 8152 380
WEBSITE: www.heine.com/de/start/
EMAIL: lseemueller@heine.com
CONTACT NAME: Lena Seemüller

In 1946 our founder, Helmut A. Heine started HEINE Optotechnik with one goal in mind; building the highest quality diagnostic instruments available in the world. It was his belief that the highest quality instruments will always best support the health care professional in making the earliest and most accurate diagnosis.

IGEA Medical UK

F20

Suites 1 & 2, Parkhill Business Annexe, Walton Road, Wetherby LS22 5DZ

TEL: 01937 547065
WEBSITE: www.igeamedical.co.uk
EMAIL: j.moser@igeamedical.com
CONTACT NAMES: Roya Davies, Jennifer Moser

For over 12 years, through a commitment to research and innovation IGEA has partnered with leading scientific institutions across Europe and developed an innovative approach to treating cutaneous and sub-cutaneous tumours (cancers affecting the skin and below the skin's surface) via the technique of clinical electroporation and electrochemotherapy using the IGEA CLINIPORATOR™ device.

Intrapharm Laboratories

J6

Courtyard Barns, Choke Lane, Maidenhead, Berkshire, SL6 6PT

TEL: 07500905546
WEBSITE: http://www.intrapharmlabs.com/
EMAIL: masih@riemser.com
CONTACT NAME: Alf Masih

Intrapharm Laboratories was founded in 1999, aiming to become an essential pharmaceutical supplier to the NHS with an ongoing supply of niche pharmaceutical medicines with a proven therapeutic value. The main products offered by Intrapharm are AquaMax Emollients, Jylamvo (oral methotrexate solution) and Terra Cortril.

Janssen-Cilag Ltd

J25

50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG

TEL: 01494 567567
WEBSITE: http://www.janssen.com/uk/

Johnson & Johnson

J20

Foundation Park, Roxborough Way, Maidenhead, Berkshire, SL6 3UG

TEL: +44 (0)1628 822222
WEBSITE: www.jnj.com
EMAIL: wmarti40@its.jnj.com
CONTACT NAME: William Martin

Caring for the world, one person at a time, inspires the people of Johnson & Johnson Ltd. We embrace research and science; bringing together innovative ideas and products to advance the health and well-being of people. Visit the stand to find out about the newest offerings from AVEENO® and NEUTROGENA®.

LD Path Group

H9

6 St Johns Place, Farringdon, London, EC1M 4NP

TEL: 0207 336 0921
WEBSITE: www.ldpath.com
EMAIL: operations@ldpath.com
CONTACT NAME: Sanj Lallie

Premium Histopathology Provider

LEO Pharma UK/IE

G15

Horizon, Honey Lane, Hurley, Berkshire, SL6 6RJ

TEL: 01844 347333
WEBSITE: www.leo-pharma.co.uk and www.leo-pharma.ie
EMAIL: comms@leo-pharma.com

Founded in 1908 and owned by the LEO Foundation, LEO Pharma helps people achieve healthy skin in over 100 countries. We are shaping the future of medical dermatology by investing in partnerships and innovation aimed at discovering new care solutions.

Headquartered in Denmark LEO Pharma employs around 5,000 people worldwide. Twitter: @LEOPharmaUKIE

LEO® © LEO, JANUARY 2018, ALL LEO TRADEMARKS
UK/IE/MAT-14507 January 2018



L’OREAL Village

G30

L’Oréal Active Cosmetics Division, 255 Hammersmith Road, London W6 8AZ

TEL: 0208 7624 000
WEBSITE: www.laroche-posay.co.uk and www.cereve.co.uk
EMAIL: Carlos.Otalora@loreal.com
CONTACT NAME: Carlos Otalora, Senior Medical Relations Manager UK and Ireland

L’Oréal Active Cosmetics Division (ACD) We are dedicated to meeting a range of different daily skin care needs from sensitive and allergic, to acne or eczema prone skin as well as anti-ageing. Our brands which include La Roche-Posay, CeraVe, Vichy and SkinCeuticals are available from pharmacies worldwide. Thanks to its highly complementary product rage developed by health professionals, it is why Dermatologists, Paediatricians, Oncologists, General Practitioners and Cosmetic Doctors trust L’OREAL ACD and have made it possible to be the world leader in dermocosmetics.

Mavig/Athrodax

D4

Unit 1, Hawthorn Business Park, Drybrook, Gloucestershire GL17 9HP

TEL: 01594 544440
WEBSITE: www.athrodax.co.uk
EMAIL: sales@athrodax.co.uk
CONTACT NAME: Eve Hall

Athrodax and partner Mavig will be demonstrating the non-invasive Vivascope Confocal laser scanning microscopy (CLSM) system which opens a ‘window into the skin’. This technology enables a real-time biopsy of the skin. Living tissue can be analyzed without excising a pathological specimen.

medac Pharma

A30

Scion House, Stirling University Innovation Park, Stirling, FK9 4NF

TEL: 01786 458059
WEBSITE: www.medacpharma.co.uk
EMAIL: info@medacpharma.co.uk
CONTACT NAME: Lauren Addison

medac Pharma is a privately owned, pharmaceutical company known for developing innovative products which help make a positive difference to the lives of our patients. Our product Metoject PEN® is licensed for severe recalcitrant disabling psoriasis and severe psoriatic arthritis in adult patients. Come visit us at stand A30.

Medical Billing and Collection

A25

Connery House, Repton Place, Amersham, Bucks HP7 9LP

TEL: 01494 763999
WEBSITE: www.medbc.co.uk
EMAIL: sbrignall@medbc.co.uk
CONTACT NAME: Simon Brignall

Medical Billing and Collection has over 26 years of experience in assisting private consultants, groups, clinics and hospitals with their billing that has enabled us to grow, predominantly through referral, to over 1000 practitioners. Clients benefit from bad debts of less than 0.5% and increases in income of up to 25%.

Medical Defence Union

E32

MDU Services Limited, One Canada Square, London, E14 5GS

TEL: 0800 716 376
WEBSITE: www.themdu.com
EMAIL: membership@themdu.com
CONTACT NAME: Ruth Burgoin

At the MDU we offer our members expert guidance, support and defence if their clinical competence or care of patients is questioned. Our team is led and staffed by doctors with experience of the pressures and challenges faced in practice. We are on your side and by your side.

Mylan UK

B10

4 Trident Place, Mosquito Way, Hatfield, AL10 9UL

TEL: 01707 853 000
WEBSITE: Mylan.co.uk
EMAIL: Fiona.Betts@mylan.co.uk
CONTACT NAME: Fiona Betts

Mylan, a global pharmaceutical company, is committed to setting new standards in healthcare, marketing a growing portfolio (7,500 products) in more than 165 countries and territories. Mylan is a large producer of active pharmaceutical ingredients. Our 35,000-strong workforce is dedicated to creating better health. Learn more at mylan.com and mylan.co.uk

Novartis Pharmaceuticals UK Limited

F10+F14+G20

Novartis Pharmaceuticals UK Limited, 200 Frimley Business Park Frimley/Camberley, Surrey GU16 7SR

TEL: 01276 692255
WEBSITE: www.novartis.co.uk

Novartis transform patients’ lives by targeting progressive illnesses in the Specialty Dermatology and Rheumatology fields, where there are high unmet medical needs.

Philips Light & Health

A10

High Tech Campus 5, 5656 AE Eindhoven, The Netherlands

TEL: 07813 891711
WEBSITE: https://www.philips.co.uk/healthcare/medical-specialties/dermatology-therapy-light-treatment
EMAIL: sara.mccracken@philips.com
CONTACT NAME: Sara McCracken

Royal Philips of the Netherlands is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the area of Healthcare. Philips Light & Health is a business unit within Philips Emerging Businesses that develops and commercializes LED-based medical devices providing patients and dermatologists with innovative solutions to treat multiple skin conditions at home or in the hospital.

Purple Orchid Pharma Ltd

E1

PO Box 15709, Dunblane FK15 5BA

TEL: 0844 415 2420
WEBSITE: www.purpleorchidpharma.com
EMAIL: kay.cox@purpleorchidpharma.com
CONTACT NAME: Kay Cox

Purple Orchid offers Loyon® – a safe, gentle keratolytic for psoriasis and cradle cap. Its non-toxic, odourless formula treated 95% of responding psoriasis patients successfully in less than 7 days. It’s non-chemical, mechanical mode of action makes it suitable for all patients including infants and the elderly without side effects.

RB

J10

Wellcroft House, Wellcroft Road, Slough, SL1 4AQ

TEL: 01753 506800
WEBSITE: www.rb.com

Sandoz

B1

200 Frimley Business Park, Frimley/ Camberley, Surrey, GU16 7SR

TEL: 01276 698020
WEBSITE: www.sandoz.uk.com

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high- quality medicine.

Sanofi Genzyme

B20

One Onslow Street, Guildford, Surrey, GU1 4SY

TEL: 01483 505 515
WEBSITE: www.sanofi.co.uk

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat. Our Aim is to translate our research and experience into results that have a real life impact on patients' lives.

Schuco

G10

Axis 4, Rhodes Way, London, WD24 4YW

TEL: 01923 234 600
WEBSITE: www.schuco.co.uk
EMAIL: sales@schuco.co.uk

Our focus on ensuring we deliver the most innovative solutions in Dermatology to deliver ground breaking clinical outcomes, our expertise allows you to be confident that we are on hand to deliver support, from picking the right products to understanding how to integrate the latest technology into your patients care.

STD Pharmaceutical Products Ltd

E30

Plough Lane, Hereford, HR4 0EL

TEL: 01432 373555
WEBSITE: www.sweathelp.co.uk
EMAIL: roliver@stdpharm.co.uk
CONTACT NAME: Richard Oliver

STD Pharmaceutical Products Ltd is a small family run company that supplies iontophoresis machines and other products to help patients with hyperhidrosis, all available through their website www.sweathelp.co.uk. We also provide extensive information on hyperhidrosis and support for patients, carers and healthcare professionals at www.hyperhidrosisuk.org.

Syneron Candela

A1

The Charter Building Uxbridge Middlesex UB8 1JG

TEL: +44 (0)8455210698
WEBSITE: https://syneron-candela.com/uk
EMAIL: ukinfo@syneron-candela.com

Thornton & Ross

C30

Thornton and Ross, Manchester Road, Linthwaite, Huddersfield, HD7 5QH

TEL: 01484 842217
WEBSITE: http://www.thorntonross.com/
EMAIL: sophiegledhill@thorntonross.com
CONTACT NAME: Sophie Gledhill

Flexitol- offering a medically proven regime for dry, cracked heels and feet associated with diabetic anhidrosis with effective, rapid treatment with Flexitol 25% Urea Heel Balm and everyday maintenance with Flexitol 10% Urea Cream.

Cetragen emollient range- specifically developed to enable effective management of eczema and problematic, dry skin.

UCB Pharma Ltd

J15

208 Bath Road, Slough, SL1 3WE

TEL: 01753 534 655
WEBSITE: www.ucbpharma.co.uk
EMAIL: info-uk@ucb.com

Waldmann/Athrodax

D3

Hawthorn Business Park, Drybrook, Gloucestershire GL17 9HP

TEL: 01594 544440
WEBSITE: www.athrodax.co.uk
EMAIL: sales@athrodax.co.uk
CONTACT NAME: Eve Hall

Athrodax and our partner Waldmann will be displaying one of the latest full body phototherapy cabins along with a selection of free standing and hand held diagnostic examination luminaires and dermatoscopes. We are also pleased to introduce the zipline skin closure system as an alternative to sutures and glues.

Wisepress Ltd


G3

15 Lyon Rd, London SW19 2RL

TEL: +44 20 8715 1812
WEBSITE: www.wisepress.com
EMAIL: bookshop@wisepress.com
CONTACT NAME: Danny Wood

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

Map of Edinburgh



Social Venues

- 1** **EICC Venue - 150 Morrison St, Edinburgh EH3 8EE**
98th BAD Annual Meeting, BADfest, DermSchool / Trainee event
- 2** **Edinburgh Castle - Castlehill, Edinburgh EH1 2NG**
Presidents' Private dinner

- 3** **Surgeons Hall - Nicolson Street, Edinburgh, EH8 9DW**
BSDS Dinner
- 4** **Omar Khayyam - 1 Grosvenor St, Edinburgh EH12 5ED**
SAS and BSMD Curry venue

Upcoming Meetings

Survival Guide for New Trainees

Thursday 2nd August 2018

Willan House, London

The Survival Guide for New Trainees course is an afternoon designed by Dr Piu Banerjee to introduce newly appointed trainees to basic dermatology. A range of essential dermatological topics and demonstrations will be presented by senior dermatology trainees and consultants.

There will be some places for LAS and clinical fellows in dermatology.

Registration is free

For further information or to book your place please visit: www.eventsforce.net/bad/250/home

Organiser: Conference & Event Services from the BAD

Email: conference@bad.org.uk

Essential Cutaneous Infections Course

Monday 24th September 2018

Willan House, London

This 1-day course now in its fourth year, is aimed at StR's, Hospital Specialty Doctors and Consultants is intended to complement the established Essential Medical Dermatology course.

The day will consist of lectures and case based discussions led by national authorities in skin infections. There will be a particular emphasis on exotic infections to address a gap in many StR training programmes and many Dermatologists' experience.

Places are strictly limited, so apply early to avoid disappointment!

For full programme details or to book your place please visit: www.eventsforce.net/eci2018

DermPath Made Easy

Thursday 27th September 2018

Willan House, London

This 1-day course aims to provide an overview and introduction to dermatopathology for new dermatology registrars and those who do not have access to regular histopathology teaching. The course will give a grounding in the basics of clinicopathological interpretation, giving registrars a structure on which to hang their learning from local MDTs and CPC meetings. It may also be suitable for Core Medical Trainees hoping to start their dermatology training within the next year.

The lectures will be delivered by both dermatologists and dermatopathologists

For further information or to book your place please visit: www.eventsforce.net/bad/251/home

Psychodermatology Annual Course – BAD Co-Badged event

Friday 28th - Saturday 29th September 2018

Holiday Inn Whitechapel, 5 Cavell St, Whitechapel, London, E1 2HP

Cost: £250.00 (including accommodation and 'Practical Psychodermatology' textbook)

Lecturers: **Dr Anthony Bewley, Professor Peter Lepping, Dr Ruth Taylor, Dr Reena Shah, Dr Alia Ahmed**

Administrator: Emma Jones

Phone: +44 1582873447

Email: emma.jones@in2global.com

Clinical Dermatology Update Meeting

Wednesday 3rd - Friday 5th October 2018

Crewe Hall

As always a highly informative programme will be provided to attending delegates making the meeting one not to be missed.

For further information or to book your place please visit: www.eventsforce.net/bad/263/home

Psoriasis: translating innovation into personalised care The Psoriasis Association UK 50th Birthday Symposium. A Joint meeting with The Dowling Club

Friday 2nd November 2018, Royal College of Physicians, London, UK

The Psoriasis Association UK is celebrating its fiftieth anniversary in 2018.

Since its foundation in 1968, this highly successful patient support organisation has funded a large number of important research projects. To celebrate this, as part of the fiftieth birthday festivities, the Psoriasis Association and Dowling Club are holding an exciting joint educational symposium at the Royal College of Physicians, London.

This one-day event, which will be of interest to health care providers working with people with psoriasis, scientists and regulators, will link research outputs, particularly projects funded by the Psoriasis Association, to clinical practice.

For further information or to book your place please visit: www.eventsforce.net/bad/259/home

Conference & Event Services from The British Association of Dermatologists

The Conference & Event Services Department of the British Association of Dermatologists offers professional conference organisational services (PCO) for the association & its membership, as well as externally to other organisations

Please visit our website for further upcoming meetings organised by the department, and contact us directly if you would like to discuss an upcoming event you would like assistance in organising.

Email: conference@bad.org.uk
Phone: +44 (0)20 7391 6343
Web: www.bad.org.uk/events

Please visit www.bad.org.uk/meetings to access further information for any of the above events as well as to view other meetings of interest organised by the department.

BRITISH SKIN FOUNDATION LEADING THE FIGHT AGAINST SKIN DISEASE AND SKIN CANCER



MORE THAN 10,000 SUPPORTERS RAISING OVER £15 MILLION



600 RESEARCHERS COMPLETING 350 PROJECTS AT 25 UNIVERSITIES AND MEDICAL SCHOOLS THROUGHOUT THE UK



COUNTLESS LIVES CHANGED THROUGH MORE THAN TWO DECADES OF BRITISH SKIN FOUNDATION FUNDING

For further information and to find out how you can help, please visit:
www.britishskinfoundation.org.uk call 0207 391 6341
www.facebook.com/leadingthefightagainstskindisease
[@BSFCharity](https://www.instagram.com/BSFCharity)



BAD 2018 Meeting App

- Review agenda & speakers
- Customise your own agenda
- Interactive floorplans
- View abstracts & e-posters
- View sponsors & exhibitors

DOWNLOAD NOW!




search for British Association of Dermatologists and Download for **FREE**




acnesupport

Offering you impartial, expert advice on acne


How can we help you?



Hormone Therapy



Myths



Range of Acne Topics

Acne Support offers guidance across a range of topics, including: what causes acne, what you can do to treat and prevent acne, the different types of acne scarring, how you can cover up acne, and what you can do if you are feeling distressed

Expert Information

On Acne Support you will find useful information and practical tips provided to you by a variety of experts, such as consultant dermatologists, skin camouflage practitioners and psychodermatologists

Myth Busting

Acne myths and misinformation can lead people to try all sorts of things to prevent and treat acne. Acne Support's team of experts have addressed some of the more common acne myths to help set the record straight

GDPR AND YOUR PERSONAL DATA AT THE BAD ANNUAL MEETING

We take the security of your data seriously and would like you to please take the time to read this information. Further details can be found in the events section of the BAD privacy Policy on the BAD website.

1. Delegate lists. The information displayed on your delegate badge will be listed in the official delegate list made available to the venue, exhibiting companies and all attendees at the venue on request. This will feature your name and institution.
2. Your RFID badge allows you to touch into sessions. Your data is recorded by the appointed company TFI who then produce the CPD certificates which will be emailed to you and can be accessed via the app.
3. The RFID badge lead capture system can also be hired by companies for use on their stand and at their symposia. Please note that if you agree to touch in your badge the company will receive a report with your name, position and postal address as per your registration input. They will also receive the email address you have specified in the relevant section registration process. A signed agreement will be made with the company receiving the data confirming that the data be used to contact the individual, they should then ask for your consent for further communication and or to be kept on the companies database. The data must not be provided, sold or distributed to third parties.
4. The RFID badge system also allows companies to set up an automated email that is generated when you touch in on their device. If they have opted for this automated email, you will receive an email from them but they will still only receive the specified email you have opted to provide.
5. We encourage delegates to interact with the meeting sponsors. However we remind delegates that if they complete surveys, that this data may be used by companies for advertising or other marketing purposes.

For specific details of how we manage your data in regards to events please see the event section of the Bad privacy policy, available on the BAD website.



British Association of Dermatologists

www.bad.org.uk